NOTE:    The following Minutes are provided for informational purposes only.

If you would like to obtain an official copy of these Minutes, please contact the

State Board of Pharmacy at 614/466-4143 for instructions and fee.

 

 

 

Minutes Of The Meeting

Ohio State Board of Pharmacy

August 5, 6, 7, 2002

 

MONDAY, AUGUST 5, 2002

 

10:00 a.m.

ROLL CALL

 

 

The State Board of Pharmacy convened in Room East-B, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

 

 

Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Mem­ber; and James E. Turner, R.Ph.

 

 

Also present were William T. Winsley, Executive Director; Timothy Benedict, Assistant Executive Director; William McMillen, Licensing Administrator; Mark Keeley, Legislative Affairs Administrator; David Rowland, Legal Affairs Administrator; Robert Cole, Compli­ance Supervisor; and Sally Ann Steuk, Assistant Attorney General.

 

R-2003-011

After a discussion of information received regarding the NABP/AACP District IV meeting to be held October 4-6, 2002 in Grand Rapids, Michigan, Mr. Turner moved that the Board authorize Mrs. Adelman and Mr. Winsley to attend the meeting, that their expenses be paid by the Board, and that the time spent at the meeting be considered as time worked.  The motion was seconded by Mrs. Teater and approved by the Board (Aye-7/Nay-0).

 

10:05 a.m.

Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investi­gation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code and for the purpose of conferring with an attorney for the Board regarding pending or imminent court action pursuant to Section 121.22(G)(3) of the Re­vised Code.  The motion was seconded by Mr. Lipsyc and a roll call vote was conducted by President Adelman as follows: Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

 

10:06 a.m.

Gregory Braylock, R.Ph. arrived and joined the Executive Session in progress.

 

11:35 a.m.

The Executive Session ended and the meeting was opened to the public.

 

R-2003-012

Mr. Giacalone moved that, pursuant to Section 3719.121 of the Revised Code, the Board summarily suspend the license to practice pharmacy belonging to Matthew Nourse, R.Ph. (03-1-22575) due to the fact that a continuation of his professional practice presents a danger of immediate and serious harm to others.  The motion was seconded by Ms. Eastman and approved by the Board (Aye-8/Nay-0).

 

R-2003-013

Mr. Giacalone then moved that the Board accept the settlement offer as revised by the Board received in the matter of Richard Ridzon, R.Ph.  The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).

 

R-2003-014

Ms. Eastman then moved that the Board deny the settlement offer from Joseph Cusma, R.Ph.  The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).

 

R-2003-015

After reviewing the documentation submitted on behalf of Michele Midlick, R.Ph., the consensus of the Board was that she has not yet complied with the requirements of her Board order.

 

11:48 a.m.

The meeting was recessed for lunch.

 

12:55 p.m.

The meeting resumed in Room East-B, 31st Floor, Vern Riffe Center for Government and the Arts with all members present.

 

  1:04 p.m.

Mr. Lipsyc moved that the Board go into Executive Session for the purpose of the investi­gation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mrs. Gregg and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

 

  1:14 p.m.

R-2003-016

The Executive Session ended and the meeting was opened to the public.  Mr. Braylock moved that the Board deny the settlement offer received in the matter of Charles Willson, R.Ph. and that the hearing be held as scheduled.  The motion was seconded by Mr. Turner and approved by the Board (Aye-8/Nay-0).

 

  1:15 p.m.

The Board took a brief recess.

 

  1:30 p.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Charles R. Willson, R.Ph., Berlin Center.

 

  6:44 p.m.

The hearing ended and the record was closed.

 

  6:45 p.m.

Mrs. Gregg moved that the Board go into Executive Session for the purpose of the investi­gation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mr. Braylock and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Giacalone-Yes, Gregg-Yes, Eastman-Yes, Lipsyc-Yes, Kost-Yes, Teater-Yes, and Turner-Yes.

 

  7:35 p.m.

R-2003-017

The Executive Session ended and the meeting opened to the public.  Mr. Braylock moved that the Board adopt the following Order in the matter of Charles R. Willson, R.Ph.:

 

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-010313-047)

 

In The Matter Of:

 

CHARLES R. WILLSON, R.Ph.

13804 Leffingwell Road

Berlin Center, Ohio  44401

(R.Ph. No. 03-3-15794)

 

 

INTRODUCTION

 

THE MATTER OF CHARLES R. WILLSON CAME FOR HEARING ON AUGUST 5, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

 

 

CHARLES R. WILLSON WAS REPRESENTED BY DAVID W. GRAUER AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

 

SUMMARY OF EVIDENCE

State's Witnesses

1.  David Gallagher, Ohio State Board of Pharmacy

2.  Timothy J. Benedict, R.Ph., Ohio State Board of Pharmacy

 

Respondent's Witnesses

1.  Charles R. Willson, R.Ph., Respondent

 

 

State's Exhibits

1.  Copy of Summary Suspension Order/Notice of Opportunity for Hearing  [03-13-01]

1A-1D.  Procedurals

1E.  Copy of Addendum Notice  [08-16-01]

1F-1H.  Procedurals

1I.  Copy of Amendment Notice  [09 20-01]

1J-1Q.  Procedurals

1R.  Copy of Addendum Notice  [07-09-02]

2.  Statement of Michael H. Linhart, R.Ph.  [03-08-01]

3.  Rx 156572

4.  Statement of Nick E. Sucaciu  [04-12-01]

5.  Rite Aid #3167 C-II Perpetual Inventory Form - OxyContin 40mg  [02-17-98 to 03-10-01]

6.  Drug Audit Accountability Sheet for Adderall 10mg at Rite Aid #3167  [04-02-01]

7.  Drug Audit Accountability Sheet for Concerta 36mg at Rite Aid #3167  [04-02-01]

8.  Drug Audit Accountability Sheet for OxyContin 10mg at Rite Aid #3167  [04-02-01]

9.  Drug Audit Accountability Sheet for OxyContin 20mg at Rite Aid #3167  [04-02-01]

 

10.  Drug Audit Accountability Sheet for OxyContin 40mg at Rite Aid #3167  [04-02-01]

11.  Drug Audit Accountability Sheet for Oxycodone/Apap 5/500mg at Rite Aid #3167  [04-02-01]

12.  Drug Audit Accountability Sheet for Oxycodone/Apap 5/325mg at Rite Aid #3167  [04-02-01]

13.  Drug Audit Accountability Sheet for Phentermine 30mg at Rite Aid #3167  [04-02-01]

14.  Drug Audit Accountability Sheet for Phentermine 37.5mg at Rite Aid #3167  [04-02-01]

15.  Drug Audit Accountability Sheet for Vicoprofen 7.5/200mg at Rite Aid #3167  [04-02-01]

16.  Drug Audit Accountability Sheet for Alprazolam .25mg at Rite Aid #3167  [04-02-01]

17.  Drug Audit Accountability Sheet for Alprazolam .5mg at Rite Aid #3167  [04-02-01]

18.  Drug Audit Accountability Sheet for Alprazolam 1mg at Rite Aid #3167  [04-02-01]

19.  Drug Audit Accountability Sheet for Alprazolam 2mg at Rite Aid #3167  [04-02-01]

20.  Drug Audit Accountability Sheet for Lorazepam 1mg at Rite Aid #3167  [04-02-01]

21.  Drug Audit Accountability Sheet for Lorazepam 2mg at Rite Aid #3167  [04-02-01]

22.  Drug Audit Accountability Sheet for Diazepam 2mg at Rite Aid #3167  [04-02-01]

23.  Drug Audit Accountability Sheet for Diazepam 5mg at Rite Aid #3167  [04-02-01]

24.  Drug Audit Accountability Sheet for Diazepam 10mg at Rite Aid #3167  [04-02-01]

25.  Drug Audit Accountability Sheet for Temazepam 15mg at Rite Aid #3167  [04-02-01]

26.  Drug Audit Accountability Sheet for Temazepam 30mg at Rite Aid #3167  [04-02-01]

27.  Drug Audit Accountability Sheet for Oxazepam 10mg at Rite Aid #3167  [04-02-01]

28.  Drug Audit Accountability Sheet for Oxazepam 15mg at Rite Aid #3167  [04-02-01]

29.  Drug Audit Accountability Sheet for Meprobamate 200mg at Rite Aid #3167  [04-02-01]

30.  Drug Audit Accountability Sheet for Meprobamate 400mg at Rite Aid #3167  [04-02-01]

31.  Rite Aid Customer History Report for Patient #8  [01-01-98 to 04-30-01]

31A.  Therapy Days/Calendar Days Comparison Report for Patient #8  [03-21-99 to 03-22-00]

32.  Rx 172456

33.  Rx 174620

 

34.  Statement of Dr. Diglisic Gordana  [02-23-01]

35.  Rite Aid Customer History Report for Patient #1  [01-01-99 to 04-25-01]

35A.  Therapy Days/Calendar Days Comparison Report for Patient #1  [01-04-99 to 02-12-01]

36.  Rx 107902

37.  Rx 108995

38.  Rx 109647

39.  Rx 110304

40.  Rx 110945

 

41.  Rx 111648

42.  Rx 112443

43.  Rx 113221

44.  Rx 115411

45.  Rx 116586

46.  Rx 117183

47.  Rx 117881

48.  Rx 118476

49.  Rx 119014

50.  Rx 120178

51.  Rx 120766

52.  Rx 121284

53.  Rx 121847

54.  Rx 122384

55.  Rx 122912

56.  Rx 123454

57.  Rx 123680

58.  Rx 124375

59.  Rx 124890

60.  Rx 125603

61.  Rx 126031

62.  Rx 127050

63.  Rx 127898

64.  Rx 129044

65.  Rx 129708

 

66.  Rx 130313

67.  Rx 131561

68.  Rx 133942

69.  Rx 134576

70.  Rx 135215

71.  Rx 135672

72.  Rx 136246

73.  Rx 136822

74.  Rx 137475

75.  Rx 138758

76.  Rx 140060

77.  Rx 140297

78.  Rx 140918

79.  Rx 141326

80.  Rx 141327

81.  Rx 141932

82.  Rx 142558

83.  Rx 143202

84.  Rx 143748

85.  Rx 144434

86.  Rx 145054

87.  Rx 145705

88.  Rx 146410

89.  Rx 147080

90.  Rx 147696

 

91.  Rx 148247

92.  Rx 148526

93.  Rx 148837

94.  Rx 149416

95.  Rx 149415

96.  Rx 150003

97.  Rx 150575

98.  Rx 151107

99.  Rx 151799

100.  Rx 152147

101.  Rx 152760

102.  Rx 153274

103.  Rx 154357

104.  Rx 154829

 

105.  Rx 155372

106.  Rx 158749

107.  Rx 159782

108.  Rx 160384

109.  Rx 161081

110.  Rx 162954

111.  Rx 163571

112.  Rx 164728

113.  Rx 165417

114.  Rx 166126

115.  Rx 166604

116.  Rx 167309

117.  Rx 167965

118.  Rx 168630

119.  Rx 169579

 

120.  Rx 172315

121.  Rx 172700

122.  Rite Aid Printout of Rx 173520  [06-27-01]

123.  Rx 174258

124.  Rite Aid Customer History Report for Patient #2  [01-01-95 to 04-09-01]

124A.  Therapy Days/Calendar Days Comparison Report for Patient #2  [12-28-98 to 04-28-00]

125.  Rx 107486  [12-28-98]

126.  Rx 107486 and Rx 108841  [01-15-99]

127.  Rx 110753  [02-05-99]

128.  Rx 110753  [02-24-99]

129.  Rx 114580  [03-12-99]

130.  Rx 114580  [03-12-99] and Rx 116157  [03-30-99]

131.  Rx 117992  [04-20-99] and Rite Aid Printout of Rx 116157  [03-30-99]

132.  Rx 117992  [05-08-99]

133.  Rx 117992  [05-27-99]

134.  Rx 126066, Rx 126067, and Rx 126068  [08-04-99]

135.  Rx 126067  [08-22-99]

136.  Rx 126066 and Rx 126067  [09-08-99]

137.  Rx 130697

138.  Rx 132971  [10-26-99] and Rite Aid Printout of Rx 130697  [09-30-99]

139.  Rx 132971  [11-16-99]

140.  Rx 136169  [12-04-99]

141.  Rx 136169  [12-22-99]

142.  Rx 139260  [01-07-00]

143.  Rx 139260, Rx 136884, Rx 136111, Rx 136110, Rx 141147, and Rx 141146  [01-28-00]

144.  Rx 139260  [02-14-00]

145.  Rx 144806  [03-09-00]

146.  Rx 144806, Rx 138424, Rx 142192, and Rx 142193  [04-01-00]

 

147.  Rx 149280, Rx 149281, and Rx 149282  [04-28-00]148.  Rite Aid Customer History Report for Patient #3  [01-01-99 to 04-24-01]

148A.  Therapy Days/Calendar Days Comparison Report for Patient #3  [03-02-99 to 10-08-99]

149.  Rx 115068  [03-18-99]

150.  Rx 115068, Rx 116760, and Rx 116761  [04-06-99]

151.  Rx 115068  [04-16-99]

152.  Rx 117850

 

153.  Rx 113313  [03-02-99]

154.  Rx 113313, Rx 113312, Rx 109765, and Rx 108434  [04-01-99]

155.  Rx 117852

156.  Rx 118466  [04-26-99]

157.  Rx 118466  [04-30-99]

158.  Rx 119036 and 119037  [05-03-99]

159.  Rx 119976

160.  Rx 119036  [05-18-99]

161.  Rx 119036, Rx 109765, Rx 116340, and Rx 109473  [06-16-99]

162.  Rx 119036, Rx 119037, and Rx 116513  [07-02-99]

163.  Rx 119036  [07-17-99]

 

164.  Rx 125963  [08-02-99]

165.  Rx 125963  [08-19-99]

166.  Rx 125963  [08-27-99]

167.  Rx 127996  [08-31-99]

168.  Rx 127996  [09-13-99]

169.  Rx 129685

170.  Rx 131447

171.  Rite Aid Customer History Report for Patient #4  [01-01-95 to 03-08-01]

171A.  Therapy Days/Calendar Days Comparison Report for Patient #4  [02-12-98 to 12-06-98]

172.  Rite Aid Printout of Rx 82946  [02-12-98]

173.  Rx 84341

174.  Rx 86049

175.  Rx 87555

176.  Rx 89483

177.  Rx 91136  [06-05-98]

178.  Rx 91136  [07-05-98]

179.  Rx 94234

180.  Rx 95990

181.  Rite Aid Printout of Rx 98345

182.  Rx 99663  [09-28-98]

183.  Rx 99663  [10-12-98]

184.  Rx 101837

185.  Rx 103319

186.  Rx 103697

187.  Rx 104432  [11-20-98]

188.  Rx 105076

189.  Rx 104432  [12-04-98]

190.  Rx 104432  [12-06-98]

191.  Rx 84342

192.  Rx 84681

193.  Rx 85607

194.  Rx 85671

195.  Rx 86048

196.  Rx 87336

197.  Rx 87556

198.  Rx 88253

199.  Rx 97257

200.  Rx 98496

 

201.  Rite Aid Printout of Rx 100689

202.  Rx 102062

203.  Rx 102546

204.  Rx 103038

205.  Rx 103803

206.  Rite Aid Printout of Rx 104766

207.  Rite Aid Customer History Report for Patient #5  [01-01-99 to 04-25-01]

207A.  Therapy Days/Calendar Days Comparison Report for Patient #5  [07-07-99 to 02-10-01]

208.  Rx 124089  [07-07-99]

209.  Rx 124089  [07-12-99]210.  Rx 125089  [07-21-99]

211.  Rite Aid Printout of Rx 125089  [07-27-99]

212.  Rx 124089 and Rx 124090 [08-01-99]

213.  Rx 124089  [08-03-99]

214.  Rx 124089  [08-19-99]

215.  Rx 124089  [09-03-99]

 

216.  Rx 129875  [09-21-99]

217.  Rx 129875 and Rx 129873  [09-24-99]

218.  Rx 139324  [01-08-00]

219.  Rx 139324  [01-12-00]

220.  Rx 139324  [01-27-00]

221.  Rx 139324 and Rx 141487  [02-01-00]

222.  Rx 141487  [02-11-00]

223.  Rx 141487  [03-01-00]

 

224.  Rx 145317 and Rx 145318  [03-15-00]

225.  Rx 145317  [03-24-00]

226.  Rx 145317  [03-31-00]

227.  Rx 145317  [04-09-00]

228.  Rx 145317 and Rx 146839  [04-12-00]

229.  Rx 149465  [05-01-00]

230.  Rx 149465  [05-10-00]

231.  Rx 151803

232.  Rx 152940  [06-12-00] and Rx 152417  [06-14-00]

233.  Rx 152940 and Rx 152417  [06-22-00]

234.  Rx 154989  [07-11-00]

235.  Rx 154989 and Rx 154987  [07-18-00]

236.  Rx 154989 and Rx 154987  [07-21-00]

237.  Rx 154989  [07-24-00]

238.  Rx 168024

239.  Rx 168627  [12-18-00]

240.  Rx 168627  [12-24-00]

241.  Rx 168627 and Rx 168626  [12-26-00]

242.  Rx 168627  [12-28-00]

243.  Rx 171917

244.  Rx 173117 and Rx 171918  [02-01-01]

245.  Rx 173117  [02-06-01]

246.  Rx 173117 and Rx 171918  [02-10-01]

247.  Rx 165203  [11-10-00]

248.  Rx 165203  [11-13-00]

249.  Rx 165203  [11-25-00]

250.  Rx 168031

251.  Rx 168626  [12-18-00]

252.  Rx 168626  [12-24-00]

253.  Rx 168626  [12-26-00]

254.  Rx 169313  [12-28-00]

255.  Rx 169313  [01-02-01]

256.  Rx 169313  [01-05-01]

256A.  Rx 169313  [01-05-01]

257.  Rx 169313  [01-08-01]

 

258.  Rx 171918  [01-22-01]

260.  Rx 171918  [02-06-01]

262.  Rite Aid Customer History Report for Patient #6  [01-01-99 to 04-25-01]

262A.  Therapy Days/Calendar Days Comparison Report for Patient #6  [10-12-00 to 02-14-01]

263.  Rx 162657  [10-12-00]

264.  Rx 162657  [10-26-00]

265.  Rx 164636  [11-04-00]

266.  Rx 164636  [11-16-00]

267.  Rx 164636  [11-24-00]

268.  Rx 164636  [11-28-00]

269.  Rx 168029  [12-04-00]

269A.  Rx 164636  [12-04-00]

270.  Rx 168029  [12-18-00]

271.  Rx 169847

272.  Rx 170672  [01-09-01]

273.  Rx 170672  [01-14-01]

 

274.  Rx 172204  [01-24-01]

275.  Rx 172204  [02-01-01]

276.  Rx 172204  [02-07-01]

277.  Rx 172204  [02-14-01]

278.  Rite Aid Customer History Report for Patient #7  [06-01-98 to 03-01-01]

278A.  Therapy Days/Calendar Days Comparison Report for Patient #7  [10-14-99 to 01-03-00]

279.  Rx 131917  [10-14-99]

280.  Rx 131917  [[10-16-99]

281.  Rx 131917  [10-21-99]

282.  Rx 131917  [10-25-99]

283.  Rx 131917  [10-29-99]

 

284.  Rx 133467  [11-01-99]

285.  Rx 133467  [11-03-99]

286.  Rx 133903  [11-07-99]

287.  Rx 133903  [11-08-99]

288.  Rx 133903  [11-12-99]

289.  Rx 134374

290.  Rx 135183  [11-21-99]

291.  Rx 135183  [11-26-99]

292.  Rx 135183  [11-28-99]

293.  Rx 135183 and Rx 136242  [12-06-99]

294.  Rx 136590

295.  Rx 135183 and Rx 137182  [12-16-99]

296.  Rx 138182  [12-27-99]

297.  Rx 138182  [12-28-99]

298.  Rx 138182  [12-29-99]

299.  Rx 138182  [01-02-00]

300.  Rx 138182  [01-03-00]

301.  Rx 119088, Rx 119089, Rx 119090, and Rx 119091  [05-03-99]

302.  Rx 123689

303.  Rx 126039  [08-03-99]

304.  Rx 126039  [08-10-99]

305.  Rx 128231  [09-02-99]

306.  Rx 128231  [09-05-99]

307.  Rx 128231  [09-08-99]

308.  Rx 129214  [09-14-99]

309.  Rx 129214  [09-23-99]

310.  Rx 131322

311.  Rx 131720

312.  Rx 133429

 

313.  Rx 115374

314.  Rx 115373

315.  Rx 118184

316.  Rx 118186

317.  Rx 121042

318.  Rx 121568

319.  Rx 122869

320.  Rx 127357

321.  Rx 128729

322.  Rx 129915

323.  Rx 130164

324.  Rx 131321

325.  Rx 132420

 

326.  Rx 132718

327.  Rx 135324

328.  Rx 135325

329.  Rx 137810 and Rx 137814  [12-23-99]

330.  Rx 137811 and Rx 137813  [12-23-99]

331.  Rx 140546

332.  Rx 140547

334.  Rx 143275

335.  Rx 143276

336.  Rx 145940

337.  Rx 145941

338.  Rite Aid Customer History Report for Patient #9  [01-01-98 to 04-30-01]

338A.  Therapy Days/Calendar Days Comparison Report for Patient #9  [12-09-98 to 04-13-00]

339.  Rx 106111  [12-09-98]

340.  Rx 106111  [12-13-98]

341.  Rx 106111  [12-16-98]

342.  Rx 106111  [12-20-98]

343.  Rx 106111  [12-24-98]

344.  Rx 106111  [12-28-98]

 

345.  Rx 127465  [08-24-99]

346.  Rx 127465  [00-00-00]

347.  Rx 127465  [09-13-99]

348.  Rx 127465  [09-24-99]

349.  Rx 127465  [10-05-99]

350.  Rx 131899  [10-14-99]

351.  Rx 131899  [10-22-99]

352.  Rx 131899  [11-01-99]

353.  Rx 141264  [01-31-00]

354.  Rx 141264  [02-22-00]

355.  Rx 141264  [03-22-00]

356.  Rx 141264  [04-13-00]

357.  Rite Aid Customer History Report for Patient #10  [03-01-98 to 05-11-00]

357A.  Therapy Days/Calendar Days Comparison Report for Patient #10  [01-08-99 to 10-20-99]

358.  Rx 108422  [01-08-99]

359.  Rx 108422  [01-22-99]

360.  Rx 110954  [02-08-99]

361.  Rx 110954  [02-20-99]

362.  Rx 113367

363.  Rx 122544

364.  Rx 123697

365.  Rx 124468  [07-13-99]

366.  Rx 124468  [07-14-99]

367.  Rx 125703

 

368.  Rx 126533

369.  Rite Aid Printout of Rx 127256

370.  Rx 127663  [08-26-99]

371.  Rx 127663  [08-27-99]

372.  Rx 128548

373.  Rx 129016

374.  Rx 129515

375.  Rx 130141

376.  Rx 130273 and Rx 130274

377.  Rx 131069

378.  Rx 131473

379.  Rx 132488

380.  R.Ph. Linhart handwritten notes for sales of OxyContin to Patient #10

381.  Rx 138885

382.  Indictment of Charles R. Willson, Case No. 2001CR0433B, Stark County Common Pleas Court  [04-10-01]

383.  Judgment Entry, Change of Plea, and Pre-Sentence Investigation.  State of Ohio vs. Charles R. Willson, Case No. 2001CR0433B, Stark County Court of Common Pleas  [05-22-01]

384.  Judgment Entry, Community Control Denied, and Prison Sentence Imposed.  State of Ohio vs. Charles R. Willson, Case No. 2001CR0433B, Stark County Court of Common Pleas  [06-22-01]

385.  Copy of Rules 4729-5-20 and 4729-5-22 of the Ohio Administrative Code

 

 

Respondent's Exhibits

A-M.  Letters of Support from Cathyrn L. Russell [05-02-01]; Bonnie J. Lewis [04-29-01]; Sandra K. Pelley [03-30-01]; Diana Priest, Ron Priest, and Dave Priest [04-05-01]; Charles and Jean Husat [not dated]; Randall E. Davis [not dated]; Andy. Ney and Dotty Ney [03-29-01]; Velma E. Glass [04-27-01]; Sylvia Handy [04-03-01]; Arthur P. Boehm and Rose M. Boehm [not dated]; Don Denny [04-18-01]; Charlene Fields and Lynn E. Fields [01-30-02]; Alice Kerns [01-30-02]

N.  Letter from Chuck Willson [03-26-01]

 

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the follow­ing to be fact:

 

 

(1)  Records of the State Board of Pharmacy indicate that Charles Raymond Willson was originally licensed by the State of Ohio as a Pharmacist on March 26, 1985, pursuant to reciprocity, and that his license to practice pharmacy in Ohio was summarily suspended effective March 13, 2001.  Records further reflect that Charles Raymond Willson was the Responsible Pharmacist at Rite Aid Discount Pharmacy #3167 pursuant to Sections 4729.27 and 4729.55 of the Ohio Revised Code and Rule 4729-5-11 of the Ohio Administrative Code.

 

 

(2)  Charles R. Willson did, from July 5, 2000, through August 1, 2000, knowingly sell a con­trolled substance in an amount less than the bulk amount when the conduct was not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: with­out a prescription and without a legitimate medical purpose, Charles R. Willson sold 160 capsules of Oxazepam 15mg., a Schedule III controlled substance.  Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

 

(3)  Charles R. Willson did, from July 5, 2000, through August 1, 2000, knowingly sell a con­trolled substance in an amount less than the bulk amount when the conduct was not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: with­out a prescription and without a legitimate medical purpose, Charles R. Willson sold 50 tab­lets of Diazepam 10mg., a Schedule III controlled substance.  Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

 

(4)  Charles R. Willson did, on or about August 1, 2000, intentionally make and/or know­ingly possess a false or forged prescription, to wit: Charles R. Willson created false entries on Prescription (Rx) 156572, which had been written for 100 tablets of OxyContin 40mg, in order to cover for his illegal sale of 84 tablets of the drug to an individual other than the actual patient, and he maintained the false prescription on file in the pharmacy to cover for the shortage.  Such conduct violates Section 2925.23(B) of the Ohio Revised Code.

 

 

(5)  Charles R. Willson as the Responsible Pharmacist did, from May 1, 1999, through March 8, 2001, fail to keep records of all controlled substances received, administered, dispensed, sold, or used, to wit: Charles R. Willson failed to account for the following controlled sub­stances at Rite Aid #3167:

 

 

 

Schedule

Drug

Strength

Shortage

 

 

 

II

Adderall

10

348

 

 

 

II

Concerta

36

59

 

 

 

II

OxyContin

10

100

 

 

 

II

OxyContin

20

174

 

 

 

II

OxyContin

40

111

 

 

 

II

oxycodone/apap

5/500

14

 

 

 

II

oxycodone/apap

5/325

684

 

 

 

III

phentermine

30

320

 

 

 

III

phentermine

37.5

6

 

 

 

III

Vicoprofen

7.5/200

1,041

 

 

 

IV

alprazolam

0.25

914

 

 

 

IV

alprazolam

0.5

2,194

 

 

 

IV

alprazolam

1

5,681

 

 

 

IV

alprazolam

2

260

 

 

 

IV

lorazepam

1

3,723

 

 

 

IV

lorazepam

2

1,130

 

 

 

IV

diazepam

2

132

 

 

 

IV

diazepam

5

2,385

 

 

 

IV

diazepam

10

2,514

 

 

 

IV

temazepam

15

4

 

 

 

IV

temazepam

30

58

 

 

 

IV

oxazepam

10

205

 

 

 

IV

oxazepam

15

357

 

 

 

IV

meprobamate

200

117

 

 

 

IV

meprobamate

400

125

 

 

 

Such conduct violates Section 3719.07 of the Ohio Revised Code and Rule 4729-9-14 of the Ohio Administrative Code.

 

 

(6)  Charles R. Willson did, on dates immediately preceding March 8, 2001, knowing that a felony had been committed, fail to report such information to law enforcement authorities, to wit: Charles R. Willson admitted to agents of the Board of Pharmacy that after he had learned that another pharmacist had  trafficked in 84 tablets of OxyContin 40mg, he agreed to aid in concealing the illegal sale by using an undispensed, on file, OxyContin 40mg prescription held for another patient.  Further, Charles R. Willson stated that he and the other pharmacist had agreed to secure the patient's cooperation by committing additional drug trafficking offenses by supplying him with controlled substances (160 capsules of oxazepam 15mg & 50 tablets of diazepam 10mg).  Such conduct violates Section 2921.22 of the Ohio Revised Code.

 

 

(7)  Charles R. Willson as the Responsible Pharmacist did, from January 4, 1999, through February 12, 2001, continuously fail to perform prospective drug utiliza­tion review and patient counseling, to wit: when dispensing medications to patients #1, #2, #3, #4, #5, #6, #7, #8, #9, and #10, pursuant to the prescriptions iterated in this Notice, Charles R. Willson and/or pharmacists under his control failed to re­view the ori­ginal prescription and/or refill information for over-utilization, incorrect drug dosage and duration of drug treatment, and misuse; and Charles R. Willson and/or pharma­cists under his control failed to offer patient counseling.  Such con­duct violates Rules 4729-5-20 and 4729-5-22 of the Ohio Administra­tive Code.

 

 

(8)  Charles R. Willson did, on or about January 26, 2001, and again on February 15, 2001, intentionally create and/or knowingly possess false or forged prescrip­tions, to wit: Charles R. Willson created documents and recorded them at Rite Aid #3167 as the below-listed prescriptions.  These documents purported to be pre­scriptions authorized by a physician, and Charles R. Willson billed them to Medi­caid.  Charles R. Willson admitted to Board of Pharmacy agents that the physician had specifically advised him that she would not author­ize said prescriptions.  How­ever, Charles R. Willson created both documents in order to cover the billing and sale of these over-the-counter substances.

 

 

 

Rx #

Dispensed

Drug

Disp. R.Ph.

Qty.

Doctor

 

 

 

172456

01-26-01

Humulin N 100U/ml

Willson

10 vials

Diglisic

 

 

 

174620

02-15-01

Insulin Syringes U100 1/2mls

Willson

10 syringes

Diglisic

 

 

 

Such conduct violates Section 2925.23(A) of the Ohio Revised Code.

 

 

(9)  Charles R. Willson as the Responsible Pharmacist did, from January 4, 1999, through February 12, 2001, sell controlled substances to patient #1 when not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others transferred controlled substances during the following instances without having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

107902

oxycodone/apap

5/325

100

 

 

 

108995

oxycodone/apap

5/325

100

 

 

 

109647

oxycodone/apap

5/325

100

 

 

 

110304

oxycodone/apap

5/325

100

 

 

 

110945

oxycodone/apap

5/325

100

 

 

 

111648

oxycodone/apap

5/325

100

 

 

 

112443

oxycodone/apap

5/325

100

 

 

 

113221

oxycodone/apap

5/325

100

 

 

 

115411

oxycodone/apap

5/325

100

 

 

 

116586

oxycodone/apap

5/325

100

 

 

 

117183

oxycodone/apap

5/325

100

 

 

 

117881

oxycodone/apap

5/325

100

 

 

 

118476

oxycodone/apap

5/325

100

 

 

 

119014

oxycodone/apap

5/325

100

 

 

 

120178

oxycodone/apap

5/325

100

 

 

 

120766

oxycodone/apap

5/325

100

 

 

 

121284

oxycodone/apap

5/325

100

 

 

 

121847

oxycodone/apap

5/325

100

 

 

 

122384

oxycodone/apap

5/325

100

 

 

 

122912

oxycodone/apap

5/325

100

 

 

 

123454

oxycodone/apap

5/325

100

 

 

 

123680

oxycodone/apap

5/325

100

 

 

 

124375

oxycodone/apap

5/325

100

 

 

 

124890

oxycodone/apap

5/325

100

 

 

 

125603

oxycodone/apap

5/325

100

 

 

 

126031

oxycodone/apap

5/325

100

 

 

 

127050

oxycodone/apap

5/325

100

 

 

 

127898

oxycodone/apap

5/325

100

 

 

 

129044

oxycodone/apap

5/325

100

 

 

 

129708

oxycodone/apap

5/325

100

 

 

 

130313

oxycodone/apap

5/325

100

 

 

 

131561

oxycodone/apap

5/325

100

 

 

 

133942

oxycodone/apap

5/325

100

 

 

 

134576

oxycodone/apap

5/325

100

 

 

 

135215

oxycodone/apap

5/325

100

 

 

 

135672

oxycodone/apap

5/325

100

 

 

 

136246

oxycodone/apap

5/325

100

 

 

 

136822

oxycodone/apap

5/325

100

 

 

 

137475

oxycodone/apap

5/325

100

 

 

 

138758

OxyContin

40

34

 

 

 

140060

oxycodone/apap

5/325

100

 

 

 

140297

OxyContin

40

60

 

 

 

140918

oxycodone/apap

5/325

100

 

 

 

141326

OxyContin

40

100

 

 

 

141327

oxycodone/apap

5/325

100

 

 

 

141932

oxycodone/apap

5/325

100

 

 

 

142558

oxycodone/apap

5/325

100

 

 

 

143202

oxycodone/apap

5/325

100

 

 

 

143748

oxycodone/apap

5/325

100

 

 

 

144434

oxycodone/apap

5/325

100

 

 

 

145054

oxycodone/apap

5/325

100

 

 

 

145705

oxycodone/apap

5/325

100

 

 

 

146410

oxycodone/apap

5/325

100

 

 

 

147080

oxycodone/apap

5/325

100

 

 

 

147696

oxycodone/apap

5/325

100

 

 

 

148247

oxycodone/apap

5/325

100

 

 

 

148526

OxyContin

40

60

 

 

 

148837

oxycodone/apap

5/325

100

 

 

 

149416

OxyContin

40

30

 

 

 

149415

oxycodone/apap

5/325

100

 

 

 

150003

oxycodone/apap

5/325

100

 

 

 

150575

oxycodone/apap

5/325

100

 

 

 

151107

oxycodone/apap

5/325

100

 

 

 

151799

oxycodone/apap

5/325

72

 

 

 

152147

oxycodone/apap

5/325

100

 

 

 

152760

oxycodone/apap

5/325

100

 

 

 

153274

oxycodone/apap

5/325

100

 

 

 

154357

oxycodone/apap

5/325

100

 

 

 

154829

oxycodone/apap

5/325

100

 

 

 

155372

oxycodone/apap

5/325

100

 

 

 

158749

oxycodone/apap

5/325

120

 

 

 

159782

oxycodone/apap

5/325

100

 

 

 

160384

oxycodone/apap

5/325

100

 

 

 

161081

oxycodone/apap

5/325

100

 

 

 

162954

oxycodone/apap

5/325

100

 

 

 

163571

oxycodone/apap

5/325

100

 

 

 

164728

oxycodone/apap

5/325

100

 

 

 

165417

oxycodone/apap

5/325

100

 

 

 

166126

oxycodone/apap

5/325

100

 

 

 

166604

oxycodone/apap

5/325

100

 

 

 

167309

oxycodone/apap

5/325

100

 

 

 

167965

oxycodone/apap

5/325

100

 

 

 

168630

oxycodone/apap

5/325

100

 

 

 

169579

oxycodone/apap

5/325

100

 

 

 

172315

oxycodone/apap

5/325

60

 

 

 

172700

oxycodone/apap

5/325

100

 

 

 

173520

oxycodone/apap

5/325

100

 

 

 

174258

oxycodone/apap

5/325

100

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

 

(10)  Charles R. Willson as the Responsible Pharmacist did, on or about January 4, 1999, through February 12, 2001, intentionally create and/or knowingly possess false or forged prescriptions for patient #1, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legiti­mate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

107902

oxycodone/apap

5/325

100

 

 

 

108995

oxycodone/apap

5/325

100

 

 

 

109647

oxycodone/apap

5/325

100

 

 

 

110304

oxycodone/apap

5/325

100

 

 

 

110945

oxycodone/apap

5/325

100

 

 

 

111648

oxycodone/apap

5/325

100

 

 

 

112443

oxycodone/apap

5/325

100

 

 

 

113221

oxycodone/apap

5/325

100

 

 

 

115411

oxycodone/apap

5/325

100

 

 

 

116586

oxycodone/apap

5/325

100

 

 

 

117183

oxycodone/apap

5/325

100

 

 

 

117881

oxycodone/apap

5/325

100

 

 

 

118476

oxycodone/apap

5/325

100

 

 

 

119014

oxycodone/apap

5/325

100

 

 

 

120178

oxycodone/apap

5/325

100

 

 

 

120766

oxycodone/apap

5/325

100

 

 

 

121284

oxycodone/apap

5/325

100

 

 

 

121847

oxycodone/apap

5/325

100

 

 

 

122384

oxycodone/apap

5/325

100

 

 

 

122912

oxycodone/apap

5/325

100

 

 

 

123454

oxycodone/apap

5/325

100

 

 

 

123680

oxycodone/apap

5/325

100

 

 

 

124375

oxycodone/apap

5/325

100

 

 

 

124890

oxycodone/apap

5/325

100

 

 

 

125603

oxycodone/apap

5/325

100

 

 

 

126031

oxycodone/apap

5/325

100

 

 

 

127050

oxycodone/apap

5/325

100

 

 

 

127898

oxycodone/apap

5/325

100

 

 

 

129044

oxycodone/apap

5/325

100

 

 

 

129708

oxycodone/apap

5/325

100

 

 

 

130313

oxycodone/apap

5/325

100

 

 

 

131561

oxycodone/apap

5/325

100

 

 

 

133942

oxycodone/apap

5/325

100

 

 

 

134576

oxycodone/apap

5/325

100

 

 

 

135215

oxycodone/apap

5/325

100

 

 

 

135672

oxycodone/apap

5/325

100

 

 

 

136246

oxycodone/apap

5/325

100

 

 

 

136822

oxycodone/apap

5/325

100

 

 

 

137475

oxycodone/apap

5/325

100

 

 

 

138758

OxyContin

40

34

 

 

 

140060

oxycodone/apap

5/325

100

 

 

 

140297

OxyContin

40

60

 

 

 

140918

oxycodone/apap

5/325

100

 

 

 

141326

OxyContin

40

100

 

 

 

141327

oxycodone/apap

5/325

100

 

 

 

141932

oxycodone/apap

5/325

100

 

 

 

142558

oxycodone/apap

5/325

100

 

 

 

143202

oxycodone/apap

5/325

100

 

 

 

143748

oxycodone/apap

5/325

100

 

 

 

144434

oxycodone/apap

5/325

100

 

 

 

145054

oxycodone/apap

5/325

100

 

 

 

145705

oxycodone/apap

5/325

100

 

 

 

146410

oxycodone/apap

5/325

100

 

 

 

147080

oxycodone/apap

5/325

100

 

 

 

147696

oxycodone/apap

5/325

100

 

 

 

148247

oxycodone/apap

5/325

100

 

 

 

148526

OxyContin

40

60

 

 

 

148837

oxycodone/apap

5/325

100

 

 

 

149416

OxyContin

40

30

 

 

 

149415

oxycodone/apap

5/325

100

 

 

 

150003

oxycodone/apap

5/325

100

 

 

 

150575

oxycodone/apap

5/325

100

 

 

 

151107

oxycodone/apap

5/325

100

 

 

 

151799

oxycodone/apap

5/325

72

 

 

 

152147

oxycodone/apap

5/325

100

 

 

 

152760

oxycodone/apap

5/325

100

 

 

 

153274

oxycodone/apap

5/325

100

 

 

 

154357

oxycodone/apap

5/325

100

 

 

 

154829

oxycodone/apap

5/325

100

 

 

 

155372

oxycodone/apap

5/325

100

 

 

 

158749

oxycodone/apap

5/325

120

 

 

 

159782

oxycodone/apap

5/325

100

 

 

 

160384

oxycodone/apap

5/325

100

 

 

 

161081

oxycodone/apap

5/325

100

 

 

 

162954

oxycodone/apap

5/325

100

 

 

 

163571

oxycodone/apap

5/325

100

 

 

 

164728

oxycodone/apap

5/325

100

 

 

 

165417

oxycodone/apap

5/325

100

 

 

 

166126

oxycodone/apap

5/325

100

 

 

 

166604

oxycodone/apap

5/325

100

 

 

 

167309

oxycodone/apap

5/325

100

 

 

 

167965

oxycodone/apap

5/325

100

 

 

 

168630

oxycodone/apap

5/325

100

 

 

 

169579

oxycodone/apap

5/325

100

 

 

 

172315

oxycodone/apap

5/325

60

 

 

 

172700

oxycodone/apap

5/325

100

 

 

 

173520

oxycodone/apap

5/325

100

 

 

 

174258

oxycodone/apap

5/325

100

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

(11)  Charles R. Willson as the Responsible Pharmacist did, from December 28, 1998, through April 28, 2000, sell controlled substances to patient #2 when not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others transferred controlled substances during the following instances without having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

107486

Ambien

10

30

 

 

 

107486

Ambien

10

30

 

 

 

110753

Ambien

10

30

 

 

 

110753

Ambien

10

30

 

 

 

114580

Ambien

10

30

 

 

 

116157

Ambien

10

30

 

 

 

117992

Ambien

10

30

 

 

 

117992

Ambien

10

30

 

 

 

117992

Ambien

10

30

 

 

 

126067

temazepam

30

30

 

 

 

126067

temazepam

30

30

 

 

 

126067

temazepam

30

30

 

 

 

130697

temazepam

30

30

 

 

 

132971

temazepam

30

30

 

 

 

132971

temazepam

30

30

 

 

 

136169

temazepam

30

30

 

 

 

136169

temazepam

30

30

 

 

 

139260

temazepam

30

30

 

 

 

139260

temazepam

30

30

 

 

 

139260

temazepam

30

30

 

 

 

144806

temazepam

30

30

 

 

 

144806

temazepam

30

30

 

 

 

149281

temazepam

30

30

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

(12)  Charles R. Willson as the Responsible Pharmacist did, on or about December 28, 1998, through April 28, 2000, intentionally create and/or knowingly possess false or forged pre­scriptions for patient #2, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legi­timate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

107486

Ambien

10

30

 

 

 

107486

Ambien

10

30

 

 

 

110753

Ambien

10

30

 

 

 

110753

Ambien

10

30

 

 

 

114580

Ambien

10

30

 

 

 

116157

Ambien

10

30

 

 

 

117992

Ambien

10

30

 

 

 

117992

Ambien

10

30

 

 

 

117992

Ambien

10

30

 

 

 

126067

temazepam

30

30

 

 

 

126067

temazepam

30

30

 

 

 

126067

temazepam

30

30

 

 

 

130697

temazepam

30

30

 

 

 

132971

temazepam

30

30

 

 

 

132971

temazepam

30

30

 

 

 

136169

temazepam

30

30

 

 

 

136169

temazepam

30

30

 

 

 

139260

temazepam

30

30

 

 

 

139260

temazepam

30

30

 

 

 

139260

temazepam

30

30

 

 

 

144806

temazepam

30

30

 

 

 

144806

temazepam

30

30

 

 

 

149281

temazepam

30

30

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

 

(13)  Charles R. Willson as the Responsible Pharmacist did, from March 2, 1999, through October 8, 1999, sell controlled substances to patient #3 when not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others sold controlled substances during the following instances without having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

115068

diazepam

5

90

 

 

 

115068

diazepam

5

90

 

 

 

115068

diazepam

5

90

 

 

 

117850

diazepam

10

3

 

 

 

113313

lorazepam

2

90

 

 

 

113313

lorazepam

2

90

 

 

 

117852

lorazepam

1

30

 

 

 

118466

lorazepam

2

14

 

 

 

118466

lorazepam

2

14

 

 

 

119036

lorazepam

2

60

 

 

 

119976

lorazepam

2

10

 

 

 

119036

lorazepam

2

60

 

 

 

119036

lorazepam

2

60

 

 

 

119036

lorazepam

2

60

 

 

 

119036

lorazepam

2

60

 

 

 

125963

lorazepam

2

60

 

 

 

125963

lorazepam

2

60

 

 

 

125963

lorazepam

2

10

 

 

 

127996

lorazepam

2

15

 

 

 

127996

lorazepam

2

15

 

 

 

129685

lorazepam

2

50

 

 

 

131447

lorazepam

2

15

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

(14)  Charles R. Willson as the Responsible Pharmacist did, on or about March 2, 1999, through October 8, 1999, intentionally create and/or knowingly possess false or forged prescriptions for patient #3, to wit Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legiti­mate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

115068

diazepam

5

90

 

 

 

115068

diazepam

5

90

 

 

 

115068

diazepam

5

90

 

 

 

117850

diazepam

10

3

 

 

 

113313

lorazepam

2

90

 

 

 

113313

lorazepam

2

90

 

 

 

117852

lorazepam

1

30

 

 

 

118466

lorazepam

2

14

 

 

 

118466

lorazepam

2

14

 

 

 

119036

lorazepam

2

60

 

 

 

119976

lorazepam

2

10

 

 

 

119036

lorazepam

2

60

 

 

 

119036

lorazepam

2

60

 

 

 

119036

lorazepam

2

60

 

 

 

119036

lorazepam

2

60

 

 

 

125963

lorazepam

2

60

 

 

 

125963

lorazepam

2

60

 

 

 

125963

lorazepam

2

10

 

 

 

127996

lorazepam

2

15

 

 

 

127996

lorazepam

2

15

 

 

 

129685

lorazepam

2

50

 

 

 

131447

lorazepam

2

15

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

 

(15)  Charles R. Willson as the Responsible Pharmacist did, from February 12, 1998, through December 6, 1998, sell controlled substances to patient #4 when not in accor­dance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others sold controlled substances during the following instances without hav­ing a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

82946

Ambien

10

30

 

 

 

84341

Ambien

10

30

 

 

 

86049

Ambien

10

30

 

 

 

87555

Ambien

10

35

 

 

 

89483

Ambien

10

20

 

 

 

91136

Ambien

10

35

 

 

 

91136

Ambien

10

35

 

 

 

94234

Ambien

10

30

 

 

 

95990

Ambien

10

30

 

 

 

98345

Ambien

10

21

 

 

 

99663

Ambien

10

35

 

 

 

99663

Ambien

10

14

 

 

 

101837

Ambien

10

30

 

 

 

103319

Ambien

10

30

 

 

 

103697

Ambien

10

20

 

 

 

104432

Ambien

10

35

 

 

 

105076

Ambien

10

30

 

 

 

104432

Ambien

10

35

 

 

 

104432

Ambien

10

35

 

 

 

84342

OxyContin

40

100

 

 

 

84681

OxyContin

40

20

 

 

 

85607

OxyContin

40

20

 

 

 

85671

OxyContin

40

100

 

 

 

86048

OxyContin

40

20

 

 

 

87336

OxyContin

40

100

 

 

 

87556

OxyContin

40

20

 

 

 

88253

OxyContin

40

20

 

 

 

97257

OxyContin

40

60

 

 

 

98496

OxyContin

40

60

 

 

 

100689

OxyContin

40

60

 

 

 

102062

OxyContin

40

60

 

 

 

102546

OxyContin

40

60

 

 

 

103038

OxyContin

40

90

 

 

 

103803

OxyContin

20

10

 

 

 

104766

OxyContin

40

60

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

 

(16) Charles R. Willson as the Responsible Pharmacist did, on or about February 12, 1998, through December 6, 1998, intentionally create and/or knowingly possess false or forged prescriptions for patient #4, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legitimate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

82946

Ambien

10

30

 

 

 

84341

Ambien

10

30

 

 

 

86049

Ambien

10

30

 

 

 

87555

Ambien

10

35

 

 

 

89483

Ambien

10

20

 

 

 

91136

Ambien

10

35

 

 

 

91136

Ambien

10

35

 

 

 

94234

Ambien

10

30

 

 

 

95990

Ambien

10

30

 

 

 

98345

Ambien

10

21

 

 

 

99663

Ambien

10

35

 

 

 

99663

Ambien

10

14

 

 

 

101837

Ambien

10

30

 

 

 

103319

Ambien

10

30

 

 

 

103697

Ambien

10

20

 

 

 

104432

Ambien

10

35

 

 

 

105076

Ambien

10

30

 

 

 

104432

Ambien

10

35

 

 

 

104432

Ambien

10

35

 

 

 

84342

OxyContin

40

100

 

 

 

84681

OxyContin

40

20

 

 

 

85607

OxyContin

40

20

 

 

 

85671

OxyContin

40

100

 

 

 

86048

OxyContin

40

20

 

 

 

87336

OxyContin

40

100

 

 

 

87556

OxyContin

40

20

 

 

 

88253

OxyContin

40

20

 

 

 

97257

OxyContin

40

60

 

 

 

98496

OxyContin

40

60

 

 

 

100689

OxyContin

40

60

 

 

 

102062

OxyContin

40

60

 

 

 

102546

OxyContin

40

60

 

 

 

103038

OxyContin

40

90

 

 

 

103803

OxyContin

20

10

 

 

 

104766

OxyContin

40

60

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

(17)  Charles R. Willson as the Responsible Pharmacist did, from November 10, 2000 through February 10, 2001, sell controlled substances to patient #5 when not in accor­dance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others sold controlled substances during the following instances with­out having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

165203

hydrocodone/apap

5/500

50

 

 

 

165203

hydrocodone/apap

5/500

50

 

 

 

165203

hydrocodone/apap

5/500

50

 

 

 

168031

hydrocodone/apap

5/500

50

 

 

 

168626

hydrocodone/apap

5/500

100

 

 

 

168626

hydrocodone/apap

5/500

30

 

 

 

168626

hydrocodone/apap

5/500

30

 

 

 

169313

hydrocodone/apap

5/500

40

 

 

 

169313

hydrocodone/apap

5/500

40

 

 

 

169313

hydrocodone/apap

5/500

40

 

 

 

169313

hydrocodone/apap

5/500

30

 

 

 

171918

hydrocodone/apap

5/500

100

 

 

 

171918

hydrocodone/apap

5/500

30

 

 

 

171918

hydrocodone/apap

5/500

40

 

 

 

171918

hydrocodone/apap

5/500

30

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

 

(17)(A)  Charles R. Willson as the Responsible Pharmacist did, from July 7, 1999, through February 10, 2001, sell dangerous drugs to patient #5 when not in accor­dance with Chap­ters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others transferred controlled substances during the follow­ing instances without having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

124089

carisoprodol

350

100

 

 

 

124089

carisoprodol

350

100

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

129875

carisoprodol

350

100

 

 

 

129875

carisoprodol

350

100

 

 

 

139324

carisoprodol

350

50

 

 

 

139324

carisoprodol

350

50

 

 

 

139324

carisoprodol

350

50

 

 

 

141487

carisoprodol

350

50

 

 

 

141487

carisoprodol

350

50

 

 

 

141487

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

149465

carisoprodol

350

50

 

 

 

149465

carisoprodol

350

50

 

 

 

151803

carisoprodol

350

50

 

 

 

152940

carisoprodol

350

50

 

 

 

152940

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

168024

carisoprodol

350

50

 

 

 

168627

carisoprodol

350

100

 

 

 

168627

carisoprodol

350

30

 

 

 

168627

carisoprodol

350

30

 

 

 

168627

carisoprodol

350

40

 

 

 

171917

carisoprodol

350

100

 

 

 

173117

carisoprodol

350

30

 

 

 

173117

carisoprodol

350

40

 

 

 

173117

carisoprodol

350

30

 

 

 

Such conduct violates Section 4729.51(C) of the Ohio Revised Code.

 

 

(18)  Charles R. Willson as the Responsible Pharmacist did, on or about July 7, 1999, through February 10, 2001, intentionally create and/or knowingly possess false or forged prescriptions for patient #5, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legitimate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

124089

carisoprodol

350

100

 

 

 

124089

carisoprodol

350

100

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

125089

carisoprodol

350

50

 

 

 

129875

carisoprodol

350

100

 

 

 

129875

carisoprodol

350

100

 

 

 

139324

carisoprodol

350

50

 

 

 

139324

carisoprodol

350

50

 

 

 

139324

carisoprodol

350

50

 

 

 

141487

carisoprodol

350

50

 

 

 

141487

carisoprodol

350

50

 

 

 

141487

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

145317

carisoprodol

350

50

 

 

 

149465

carisoprodol

350

50

 

 

 

149465

carisoprodol

350

50

 

 

 

151803

carisoprodol

350

50

 

 

 

152940

carisoprodol

350

50

 

 

 

152940

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

154989

carisoprodol

350

50

 

 

 

168024

carisoprodol

350

50

 

 

 

168627

carisoprodol

350

100

 

 

 

168627

carisoprodol

350

30

 

 

 

168627

carisoprodol

350

30

 

 

 

168627

carisoprodol

350

40

 

 

 

171917

carisoprodol

350

100

 

 

 

173117

carisoprodol

350

30

 

 

 

173117

carisoprodol

350

40

 

 

 

173117

carisoprodol

350

30

 

 

 

165203

hydrocodone/apap

5/500

50

 

 

 

165203

hydrocodone/apap

5/500

50

 

 

 

165203

hydrocodone/apap

5/500

50

 

 

 

168031

hydrocodone/apap

5/500

50

 

 

 

168626

hydrocodone/apap

5/500

100

 

 

 

168626

hydrocodone/apap

5/500

30

 

 

 

168626

hydrocodone/apap

5/500

30

 

 

 

169313

hydrocodone/apap

5/500

40

 

 

 

169313

hydrocodone/apap

5/500

40

 

 

 

169313

hydrocodone/apap

5/500

40

 

 

 

169313

hydrocodone/apap

5/500

30

 

 

 

171918

hydrocodone/apap

5/500

100

 

 

 

171918

hydrocodone/apap

5/500

30

 

 

 

171918

hydrocodone/apap

5/500

40

 

 

 

171918

hydrocodone/apap

5/500

30

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

 

(19)  Charles R. Willson as the Responsible Pharmacist did, from October 12, 2000, through February 14, 2001, sell dangerous drugs to patient #6 when not in accor­dance with Chap­ters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others transferred controlled substances during the follow­ing instances without having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

162657

carisoprodol

350

90

 

 

 

162657

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

168029

carisoprodol

350

45

 

 

 

168604

carisoprodol

350

45

 

 

 

169847

carisoprodol

350

45

 

 

 

170672

carisoprodol

350

22

 

 

 

170672

carisoprodol

350

38

 

 

 

172204

carisoprodol

350

90

 

 

 

172204

carisoprodol

350

90

 

 

 

172204

carisoprodol

350

90

 

 

 

172204

carisoprodol

350

90

 

 

 

Such conduct violates of Section 4729.51(C) of the Ohio Revised Code.

 

 

(20)  Charles R. Willson as the Responsible Pharmacist did, on or about October 12, 2000, through February 14, 2001, intentionally create and/or knowingly possess false or forged prescriptions for patient #6, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legiti­mate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

162657

carisoprodol

350

90

 

 

 

162657

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

164636

carisoprodol

350

90

 

 

 

168029

carisoprodol

350

45

 

 

 

168604

carisoprodol

350

45

 

 

 

169847

carisoprodol

350

45

 

 

 

170672

carisoprodol

350

22

 

 

 

170672

carisoprodol

350

38

 

 

 

172204

carisoprodol

350

90

 

 

 

172204

carisoprodol

350

90

 

 

 

172204

carisoprodol

350

90

 

 

 

172204

carisoprodol

350

90

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

 

(21)  Charles R. Willson as the Responsible Pharmacist did, from October 14, 1999, through January 3, 2000, sell controlled substances to patient #7 when not in accor­dance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others transferred controlled substances during the following instances without having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

131917

oxazepam

15

30

 

 

 

131917

oxazepam

15

30

 

 

 

131917

oxazepam

15

30

 

 

 

131917

oxazepam

15

15

 

 

 

131917

oxazepam

15

15

 

 

 

133467

oxazepam

15

30

 

 

 

133636

oxazepam

15

25

 

 

 

133903

oxazepam

15

30

 

 

 

133903

oxazepam

15

30

 

 

 

134374

oxazepam

15

20

 

 

 

134374

oxazepam

15

10

 

 

 

135183

oxazepam

10

100

 

 

 

135183

oxazepam

10

50

 

 

 

135183

oxazepam

10

50

 

 

 

135183

oxazepam

10

50

 

 

 

136590

oxazepam

15

30

 

 

 

135183

oxazepam

10

50

 

 

 

138182

oxazepam

15

10

 

 

 

138182

oxazepam

15

5

 

 

 

138182

oxazepam

15

45

 

 

 

138182

oxazepam

15

10

 

 

 

138182

oxazepam

15

20

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

(22)  Charles R. Willson as the Responsible Pharmacist did, on or about October 14, 1999, through January 3, 2000, intentionally create and/or knowingly possess false or forged pre­scriptions for patient #7, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legiti­mate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

131917

oxazepam

15

30

 

 

 

131917

oxazepam

15

30

 

 

 

131917

oxazepam

15

30

 

 

 

131917

oxazepam

15

15

 

 

 

131917

oxazepam

15

15

 

 

 

133467

oxazepam

15

30

 

 

 

133636

oxazepam

15

25

 

 

 

133903

oxazepam

15

30

 

 

 

133903

oxazepam

15

30

 

 

 

134374

oxazepam

15

20

 

 

 

134374

oxazepam

15

10

 

 

 

135183

oxazepam

10

100

 

 

 

135183

oxazepam

10

50

 

 

 

135183

oxazepam

10

50

 

 

 

135183

oxazepam

10

50

 

 

 

136590

oxazepam

15

30

 

 

 

135183

oxazepam

10

50

 

 

 

138182

oxazepam

15

10

 

 

 

138182

oxazepam

15

5

 

 

 

138182

oxazepam

15

45

 

 

 

138182

oxazepam

15

10

 

 

 

138182

oxazepam

15

20

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

 

(23)  Charles R. Willson as the Responsible Pharmacist did, from March 21, 1999, through March 22, 2000, sell controlled substances to patient #8 when not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others sold controlled substances during the following instances without having a valid pre­scription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

119091

oxazepam

10

30

 

 

 

123689

oxazepam

10

30

 

 

 

126039

oxazepam

10

30

 

 

 

126039

oxazepam

10

10

 

 

 

128231

oxazepam

15

30

 

 

 

128231

oxazepam

15

30

 

 

 

128231

oxazepam

15

30

 

 

 

129214

oxazepam

10

30

 

 

 

129214

oxazepam

10

30

 

 

 

131322

oxazepam

15

30

 

 

 

131720

oxazepam

10

25

 

 

 

133429

oxazepam

10

30

 

 

 

115374

OxyContin

20

60

 

 

 

115373

oxycodone/apap

5/325

30

 

 

 

118184

OxyContin

40

100

 

 

 

118186

oxycodone/apap

5/325

60

 

 

 

121042

OxyContin

40

100

 

 

 

121568

oxycodone/apap

5/325

30

 

 

 

122869

oxycodone/apap

5/325

60

 

 

 

127357

oxycodone/apap

5/325

60

 

 

 

128729

OxyContin

40

100

 

 

 

129915

oxycodone/apap

5/325

60

 

 

 

130164

OxyContin

20

30

 

 

 

131321

OxyContin

20

30

 

 

 

132420

OxyContin

40

100

 

 

 

132718

oxycodone/apap

5/325

60

 

 

 

135324

OxyContin

40

100

 

 

 

135325

oxycodone/apap

5/325

60

 

 

 

137814

OxyContin

40

60

 

 

 

137813

oxycodone/apap

5/325

60

 

 

 

140546

OxyContin

40

60

 

 

 

140547

oxycodone/apap

5/325

60

 

 

 

143275

OxyContin

40

60

 

 

 

143276

oxycodone/apap

5/325

60

 

 

 

145940

OxyContin

40

60

 

 

 

145941

oxycodone/apap

5/325

60

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

 

(24)  Charles R. Willson as the Responsible Pharmacist did, on or about March 21, 1999, through March 22, 2000, intentionally create and/or knowingly possess false or forged pre­scriptions for patient #8, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legitimate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

119091

oxazepam

10

30

 

 

 

123689

oxazepam

10

30

 

 

 

126039

oxazepam

10

30

 

 

 

126039

oxazepam

10

10

 

 

 

128231

oxazepam

15

30

 

 

 

128231

oxazepam

15

30

 

 

 

128231

oxazepam

15

30

 

 

 

129214

oxazepam

10

30

 

 

 

129214

oxazepam

10

30

 

 

 

131322

oxazepam

15

30

 

 

 

131720

oxazepam

10

25

 

 

 

133429

oxazepam

10

30

 

 

 

115374

OxyContin

20

60

 

 

 

115373

oxycodone/apap

5/325

30

 

 

 

118184

OxyContin

40

100

 

 

 

118186

oxycodone/apap

5/325

60

 

 

 

121042

OxyContin

40

100

 

 

 

121568

oxycodone/apap

5/325

30

 

 

 

122869

oxycodone/apap

5/325

60

 

 

 

127357

oxycodone/apap

5/325

60

 

 

 

128729

OxyContin

40

100

 

 

 

129915

oxycodone/apap

5/325

60

 

 

 

130164

OxyContin

20

30

 

 

 

131321

OxyContin

20

30

 

 

 

132420

OxyContin

40

100

 

 

 

132718

oxycodone/apap

5/325

60

 

 

 

135324

OxyContin

40

100

 

 

 

135325

oxycodone/apap

5/325

60

 

 

 

137814

OxyContin

40

60

 

 

 

137813

oxycodone/apap

5/325

60

 

 

 

140546

OxyContin

40

60

 

 

 

140547

oxycodone/apap

5/325

60

 

 

 

143275

OxyContin

40

60

 

 

 

143276

oxycodone/apap

5/325

60

 

 

 

145940

OxyContin

40

60

 

 

 

145941

oxycodone/apap

5/325

60

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

(25)  Charles R. Willson as the Responsible Pharmacist did, from December 9, 1998, through April 13, 2000, sell controlled substances to patient #9 when not in accor­dance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others transferred controlled substances during the follow­ing instances without having a valid prescription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

131899

hydrocodone/apap

5/500

120

 

 

 

131899

hydrocodone/apap

5/500

120

 

 

 

131899

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

(26)  Charles R. Willson as the Responsible Pharmacist did, on or about December 9, 1998, through April 13, 2000, intentionally create and/or knowingly possess false or forged pre­scriptions for patient #9, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legitimate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

106111

hydrocodone/apap

5/500

50

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

127465

hydrocodone/apap

5/500

120

 

 

 

131899

hydrocodone/apap

5/500

120

 

 

 

131899

hydrocodone/apap

5/500

120

 

 

 

131899

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

141264

hydrocodone/apap

5/500

120

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

(27)  Charles R. Willson as the Responsible Pharmacist did, from January 8, 1999, through January 21, 2000, sell controlled substances to patient #10 when not in accordance with Chapters 3719., 4729., and 4731. of the Ohio Revised Code, to wit: Charles R. Willson and others sold controlled substances during the following instances without having a valid pre­scription or a legitimate medical purpose:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

108422

hydrocodone/ibuprofen

7.5/200

60

 

 

 

108422

hydrocodone/ibuprofen

7.5/200

60

 

 

 

110954

hydrocodone/ibuprofen

7.5/200

60

 

 

 

110954

hydrocodone/ibuprofen

7.5/200

60

 

 

 

113367

hydrocodone/apap

5/500

15

 

 

 

122544

hydrocodone/ibuprofen

7.5/200

16

 

 

 

123697

hydrocodone/ibuprofen

7.5/200

30

 

 

 

124468

hydrocodone/ibuprofen

7.5/200

30

 

 

 

124468

hydrocodone/ibuprofen

7.5/200

30

 

 

 

125703

hydrocodone/apap

7.5/750

60

 

 

 

126533

hydrocodone/apap

7.5/750

60

 

 

 

127256

hydrocodone/apap

7.5/750

60

 

 

 

127663

hydrocodone/ibuprofen

7.5/200

30

 

 

 

127663

hydrocodone/ibuprofen

7.5/200

30

 

 

 

128548

hydrocodone/ibuprofen

7.5/200

30

 

 

 

129016

hydrocodone/ibuprofen

7.5/200

30

 

 

 

129515

hydrocodone/ibuprofen

7.5/200

30

 

 

 

130141

hydrocodone/ibuprofen

7.5/200

60

 

 

 

130273

hydrocodone/homatropine

5/1.5

120 ml

 

 

 

131069

hydrocodone/homatropine

5/1.5

120 ml

 

 

 

131473

hydrocodone/ibuprofen

7.5/200

28

 

 

 

132488

hydrocodone/ibuprofen

7.5/200

60

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

27

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

33

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

20

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

40

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

10

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

50

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

15

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

15

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

15

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

10

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

6

 

 

 

N/A

OxyContin

40

6

 

 

 

N/A

OxyContin

40

4

 

 

 

N/A

OxyContin

40

29

 

 

 

138885

OxyContin

40

44

 

 

 

Such conduct violates Section 2925.03 of the Ohio Revised Code.

 

(28)  Charles R. Willson as the Responsible Pharmacist did, on or about January 8, 1999, through January 21, 2000, intentionally create and/or knowingly possess false or forged prescriptions to patient #10, to wit: Charles R. Willson and others created and possessed on file at the pharmacy the following prescriptions not written for a legitimate medical purpose or otherwise approved by an authorized prescriber:

 

 

 

Rx #

Drug

Strength

Qty

 

 

 

108422

hydrocodone/ibuprofen

7.5/200

60

 

 

 

108422

hydrocodone/ibuprofen

7.5/200

60

 

 

 

110954

hydrocodone/ibuprofen

7.5/200

60

 

 

 

110954

hydrocodone/ibuprofen

7.5/200

60

 

 

 

113367

hydrocodone/apap

5/500

15

 

 

 

122544

hydrocodone/ibuprofen

7.5/200

16

 

 

 

123697

hydrocodone/ibuprofen

7.5/200

30

 

 

 

124468

hydrocodone/ibuprofen

7.5/200

30

 

 

 

124468

hydrocodone/ibuprofen

7.5/200

30

 

 

 

125703

hydrocodone/apap

7.5/750

60

 

 

 

126533

hydrocodone/apap

7.5/750

60

 

 

 

127256

hydrocodone/apap

7.5/750

60

 

 

 

127663

hydrocodone/ibuprofen

7.5/200

30

 

 

 

127663

hydrocodone/ibuprofen

7.5/200

30

 

 

 

128548

hydrocodone/ibuprofen

7.5/200

30

 

 

 

129016

hydrocodone/ibuprofen

7.5/200

30

 

 

 

129515

hydrocodone/ibuprofen

7.5/200

30

 

 

 

130141

hydrocodone/ibuprofen

7.5/200

60

 

 

 

130273

hydrocodone/homatropine

5/1.5

120 ml

 

 

 

131069

hydrocodone/homatropine

5/1.5

120 ml

 

 

 

131473

hydrocodone/ibuprofen

7.5/200

28

 

 

 

132488

hydrocodone/ibuprofen

7.5/200

60

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

27

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

33

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

20

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

40

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

10

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

50

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

15

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

15

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

15

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

10

 

 

 

N/A

hydrocodone/ibuprofen

7.5/200

6

 

 

 

N/A

OxyContin

40

6

 

 

 

N/A

OxyContin

40

4

 

 

 

N/A

OxyContin

40

29

 

 

 

138885

OxyContin

40

44

 

 

 

Such conduct violates Section 2925.23 of the Ohio Revised Code.

 

 

(29)  On May 18, 2001, Charles R. Willson pled guilty to one (1) count of Trafficking in Drugs, (a felony of the fifth degree) in violation of Revised Code 2925.03; one (1) count of Illegal Processing of Drug Documents, (a felony of the fourth degree) in violation of Revised Code 2925.23; and two (2) counts of Forgery, (a felony of the fifth degree) in violation of Revised Code 2913.31(A).  State of Ohio vs. Charles R. Willson, Case No. 2001CR0433B, Stark County Common Pleas Court. Charles R. Willson was incarcerated for these crimes on June 21, 2001.

 

 

CONCLUSIONS OF LAW

 

(1)  The State Board of Pharmacy concludes that paragraphs (2) through (6) and (8) through (29) of the Findings of Fact constitute being guilty of a felony and gross immorality as pro­vided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.

 

 

(2)  The State Board of Pharmacy concludes that paragraphs (2) through (29) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

 

(3)  The State Board of Pharmacy concludes that paragraphs (2) through (5) and (8) through (29) of the Findings of Fact constitute being guilty of willfully violating, conspiring to vio­late, attempting to violate, or aiding and abetting the violation of provisions of Chapters 2925., 3719., or 4729. of the Revised Code as provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

 

DECISION OF THE BOARD

 

Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby removes the Summary Suspension Order issued to Charles R. Willson on March 13, 2001.

 

 

Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy takes the following actions in the matter of Charles R. Willson:

 

 

(A)  On the basis of the Findings of Fact and paragraphs (1) and (2) of the Conclu­sions of Law set forth above, the State Board of Pharmacy hereby suspends indefi­nitely the pharma­cist identification card, No. 03-3-15794, held by Charles R. Willson and such suspension is effective as of the date of the mailing of this Order.

 

 

(1)  Charles R. Willson, pursuant to Rule 4729-9-01(F) of the Ohio Admini­strative Code, may not be employed by or work in a facility licensed by the State Board of Pharmacy to possess or distribute dangerous drugs during such period of suspen­sion.

 

 

(2)  Charles R. Willson, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return his identification card and license (wall certificate) to the office of the State Board of Pharmacy within ten days after receipt of this Order unless the Board office is already in possession of both.  The iden­tification card and wall certificate should be sent by certified mail, return receipt requested.

 

 

(B)  On the basis of the Findings of Fact and paragraph (3) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby imposes a monetary pen­alty of twenty thousand dollars ($20,000.00) on Charles R. Willson and payment of the monetary penalty is due and owing within thirty days of the mailing of this Order.  The remittance should be made payable to the "Treasurer, State of Ohio" and mailed with the enclosed form to the State Board of Pharmacy, 77 South High Street, Room 1702, Columbus, Ohio 43215-6126.

 

(C)  Further, five years from the effective date of Charles R. Willson's Summary Sus­pen­sion Order, Mr. Willson's license will be reinstated provided that the following conditions are completed during the six months immediately preced­ing the date for reinstatement of his license:

 

 

(1)  Charles Raymond Willson must take and pass the Multistate Pharmacy Juris­prudence Examination (MPJE), or an equivalent examination approved by the Board.

(2)  Charles Raymond Willson must work in a pharmacy for a minimum of 750 hours under the direct supervision of a pharmacist whose license is in good standing.

 

 

If these conditions are not fulfilled prior to March 13, 2006, Charles R. Willson's license will remain under suspension until all conditions have been achieved.

 

(D)  Upon reinstatement, the Board hereby places Charles R. Willson's license on proba­tion for ten years effective as of the date Mr. Willson's identification card to practice phar­macy is issued.  The terms of probation are as follows:

 

 

(1)  The State Board of Pharmacy hereby declares that Charles R. Willson's pharma­cist identification card is not in good standing and thereby denies the privilege of being a preceptor and training pharmacy interns pursuant to paragraph (D)(1) of Rule 4729-3-01 of the Ohio Administrative Code.

(2)  Charles R. Willson may not work alone in the pharmacy.

(3)  Charles R. Willson may not serve as a responsible pharmacist.

(4)  Charles R. Willson may not destroy, assist in, or witness the destruction of controlled substances.

(5)  Charles R. Willson must not violate the drug laws of the state of Ohio, any other state, or the federal government.

(6)  Charles R. Willson must abide by the rules of the State Board of Phar­macy.

(7)  Charles R. Willson must comply with the terms of this Order.

 

 

Charles R. Willson is hereby advised that the Board may at any time revoke probation for cause, modify the conditions of probation, and reduce or extend the period of probation.  At any time during this period of probation, the Board may revoke probation for a violation occurring during the probation period.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

 

The motion was seconded by Mr. Kost and approved by the Board (Aye-6/Nay-2).

 

  7:37 p.m.

The meeting was recessed until Tuesday, August 6, 2002.

 

 

TUESDAY, AUGUST 6, 2002

 

  8:00 a.m.

ROLL CALL

 

The State Board of Pharmacy reconvened in Room East-B, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

 

 

Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Gregory Braylock, R.Ph.; Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; and James E. Turner, R.Ph.

 

  8:03 a.m.

Mrs. Teater arrived and joined the meeting in progress.

 

Mr. Keeley presented a revised set of proposed rule changes and additions on behalf of the Ad Hoc Committee on Rule Review, continuing the discussion that was started at the August meeting.  The Board members discussed the rules and suggested some additional changes.  Mr. Keeley will make the suggested changes and return at the September meet­ing to continue the discussion.

 

  9:08 a.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Frank A. Leon, R.Ph., Lorain.

 

  9:50 a.m.

Ms. Eastman moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mr. Braylock and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Giacalone-Yes, Gregg-Yes, Eastman-Yes, Lipsyc-Yes, Kost-Yes, Teater-Yes, and Turner-Yes.

 

10:00 a.m.

The Executive Session ended and the meeting was opened to the public.

 

R-2003-018

Ms. Eastman moved to grant the request for a continuance in the matter of Joseph Cusma, R.Ph. that had been scheduled for 1:30 p.m. that afternoon.  The motion was seconded by Mrs. Gregg and approved by the Board (Aye-8/Nay-0).

 

10:05 a.m.

The hearing in the matter of Frank A. Leon, R.Ph. continued.

 

12:06 p.m.

The hearing ended and the record was closed.  The Board recessed for lunch.

 

  1:00 p.m.

The Board convened in Room 1960, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio, for the purpose of meeting with the candidates for licensure by reciprocity with the following members present:

 

 

Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Gregory Braylock, R.Ph.; Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Mem­ber; and James E. Turner, R.Ph.

 

R-2003-019

Following presentations by Board members and self-introductions by the candidates for licensure by reciprocity, Mr. Turner moved that the Board approve the following candidates for licensure.  The motion was seconded by Mr. Braylock and approved by the Board (Aye-8/Nay-0).

 

 

 

TRACY W. BECKER

03-3-25366

WEST VIRGINIA

 

 

 

LISA CARMELL BROWN

03-3-25467

KENTUCKY

 

 

 

JEFFREY MICHAEL DURKIN

03-3-25451

MICHIGAN

 

 

DIANE LYNN FOX

03-3-25258

TEXAS

 

 

STACEY VAN ZALE HAYES

03-3-25455

MICHIGAN

 

 

KATHRYN JEAN KLECKNER

03-3-25459

NEW YORK

 

 

JOSEPH ALLEN McKOWN

03-3-25273

MICHIGAN

 

 

SARAH ORAHOOD

03-3-25472

INDIANA

 

 

NAGARANI POTHUGANTI

03-3-25471

SOUTH CAROLINA

 

 

RICK THOMAS PHILLIPS

03-3-25449

INDIANA

 

 

MARY BETH PREFONTAINE

03-3-25236

MICHIGAN

 

 

CHRISTIN COLLETTE ROGERS

03-3-25454

COLORADO

 

 

YOCHEVED JACKIE RASKIND

03-3-25441

NEW YORK

 

 

JASON EDWARD STURGEON

03-3-25440

NORTH CAROLINA

 

 

CYNTHIA SUE TINDALL

03-3-25445

KENTUCKY

 

 

MARYANN TOMECHKO

03-3-25469

MINNESOTA

 

 

CRAIG WEINERT

03-3-25460

NEW YORK

 

 

HENRY JOHN WIELGOSZ

03-3-25293

ILLINOIS

 

  1:27 p.m.

The Board reconvened in Room East-B, 31st Floor to continue the Board meeting.

 

Mr. Keeley presented his Legislative Report to the Board.

 

R-2003-020

Mr. Winsley presented a request from Clinical Apothecaries (02-1146750) in Medina for an exemption to Ohio Administrative Code (OAC) Rule 4729-5-10 (Pick-up station) so that patient-specific prescriptions for a clinical study could be compounded at Clinical Apothecaries and delivered to Children’s Hospital Medical Center Pharmacy (02-0038900) for administration to patients at the hospital.  After discussion, Ms. Eastman moved that the Board approve the request due to the need for involvement by a health care profes­sional in the patient’s drug therapy [OAC Rule 4729-5-10(B)(5)(b)].  The motion was seconded by Mr. Braylock and approved by the Board (Aye-8/Nay-0).

 

R-2003-021

Mr. Winsley then presented a request from St. Vincent Charity Hospital Pharmacy (02-1185700) in Cleveland for an exemption to OAC Rule 4729-5-10 (Pick-up station) so that patient-specific prescriptions for cardioplegic, dialysis, and nutrition solutions could be prepared at Central Admixture Pharmacy Services (02-1312700) and delivered to the hospital pharmacy for administration to patients at the hospital.  After discussion, Ms. Eastman moved that the Board approve the request due to the need for involvement by a health care professional in the patient’s drug therapy [OAC Rule 4729-5-10(B)(5)(b)].  The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).

 

R-2003-022

Mr. Benedict presented a request from CVS Pharmacy (02-0519600) in Dayton for an exemption to OAC Rule 4729-5-10 (Pick-up station) so that patient-specific prescriptions for students at the University of Dayton could be prepared at CVS/pharmacy and deliv­ered to the student health center at the University of Dayton (02-0259200) for distri­bution to the students.  After discussion, Mr. Kost moved that the Board approve the request due to the need for involvement by a health care professional in the patient’s drug therapy [OAC Rule 4729-5-10(B)(5)(b)].  The motion was seconded by Mrs. Gregg and approved by the Board (Aye-8/Nay-0).

 

 

The Board next considered a letter received from Jack D. Young, attorney for Michael Fraulini (Docket D-020307-046) regarding Mr. Fraulini’s Board Order.  After discussion, the Board chose to take no action.

 

 

Mr. Braylock reported that there had been no meeting of the Nursing Board’s Committee on Prescriptive Governance.

 

There was no report on the Medical Board’s Prescribing Committee.

 

 

After discussion, Mrs. Gregg moved that the minutes of the July 2002 meeting be approved as written.  The motion was seconded by Mr. Braylock and approved by the Board (Aye-8/Nay-0).

 

  2:18 p.m.

The Board took a brief recess.

 

  2:42 p.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of James Murray Bayless, R.Ph., Fort Thomas, Kentucky.

 

  4:02 p.m.

The hearing ended and the record was closed.

 

  4:22 p.m.

Mr. Braylock moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mrs. Gregg and a roll
call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

 

  4:50 a.m.

 

The Executive Session ended and the meeting was opened to the public.

 

R-2003-023

Mr. Giacalone moved that the Board adopt the following Order in the matter of James Murray Bayless, R.Ph.:

 

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-020319-047)

 

In The Matter Of:

 

JAMES MURRAY BAYLESS, R.Ph.

1404 East Henry Clay

Fort Wright, Kentucky 41011

(R.Ph. No. 03-3-10368)

 

 

INTRODUCTION

 

THE MATTER OF JAMES MURRAY BAYLESS CAME FOR HEARING ON AUGUST 6, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

 

 

JAMES MURRAY BAYLESS WAS REPRESENTED BY ERIC J. PLINKE AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

 

SUMMARY OF EVIDENCE

State’s Witnesses

None

 

Respondent's Witnesses

1.  James Murray Bayless, R.Ph., Respondent

2.  Matthew Fischer, R.Ph.

3.  Penelope Rogers

 

 

State's Exhibits

1.  Reinstatement Hearing Request letter from Eric J. Plinke  [03-15-02]

1A-1B.  Procedurals

2.  State Board of Pharmacy Order, in re James Murray Bayless, R.Ph.  [07-17-00]

3.  Photocopy of drugs

4. 

5. 

 

 

Respondent's Exhibits

A.  State Board of Pharmacy Order in re James Murray Bayless, R.Ph  [07-17-00]

B. 

C.  Pharmacist’s Recovery Contract of James M. Bayless  [09-01-00]; letter from Michael  D. Quigley, R.Ph.  [08-04-02]; letter from Michael D. Quigley, R.Ph.  [08-05-02]

D.  Urine drug screen reports [06-28-00 to 07-06-02]

E.  Support Group Attendance Records [05-29-00 to 07-31-02]

F.  Recovery Progress letters from Thomas Cox MS, CCDCI  [07-18-02]; Diane Brock, CCDC IIIe  [12-21-00]

G.  Continuing Pharmaceutical Education Credits and Certificates [03-25-99 to 06-17-02]

 

H. 

 

I.   Letters of support for James Murray Bayless from James C. Ward  [07-25-02]; Linda Ochs  [07-23-02]; John P. Tekulve, not dated; Jay S. Belcher, R.Ph.  [07-20-02]; David White  [07-20-02]; Richard Sorrell  [07-28-02]; James F. Liebetrau, R.Ph.  [07-16-02]; Diane Brock CCDC IIIe  [07-23-02];                                                            Joseph E. Geiser, R.Ph.  [08-01-02];

 

 

FINDING OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evi­dence, and weighed the credibility of each, the State Board of Pharmacy finds that James Murray Bayless has complied with the terms set forth in the Order of the State Board of Pharmacy, Docket No. D-990908-018, effective July 17, 2000.

 

 

DECISION OF THE BOARD

 

On the basis of the Finding of Fact set forth above, the State Board of Pharmacy hereby approves the reinstatement of the pharmacist identification card, No. 03-3-10368, held by James Murray Bayless to practice pharmacy in the state of Ohio and places James Murray Bayless on probation for five years from the date the identification card is issued, with the following conditions:

 

 

(A)  James Murray Bayless must enter into a contract, signed within thirty days after the effective date of this Order, with an Ohio Department of Alcohol and Drug Addiction Ser­vices (ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of not less than five years and submit a copy of the signed contract to the Board office with the renewal application.  The contract must pro­vide that:

 

 

(1)  Random, observed urine drug screens shall be conducted each month for the first twelve months and then once every three months for the remaining four years.

 

 

(a)  The urine sample must be given within twelve hours of notifica­tion.  The urine drug screen must include testing for creatinine or specific gravity of the sample as the dilutional standard.

 

 

(b)  Alcohol must be added to the standard urine drug screen.  A Breath­alyzer may be used to test for alcohol, but an appropriately certified indi­vidual must conduct the test within twelve hours of notification.

 

 

(c)  Results of all drug and alcohol screens must be negative.  Any positive results, including those which may have resulted from ingestion of food, but excluding false positives which resulted from medication legitimately prescribed, indicates a violation of the contract and probation.

 

 

(2)  The intervener/sponsor shall provide copies of all drug and alcohol screen re­ports to the Board in a timely fashion.

 

 

(3)  Attendance is required a minimum of three times per week at an Alco­holics Anonymous, Narcotics Anonymous, and/or similar support group meeting.

 

 

(4)  The program shall immediately report to the Board any violations of the con­tract and/or lack of cooperation.

 

 

(B)  James Murray Bayless must submit quarterly progress reports to the Board (due January 10, April 10, July 10, and October 10 of each year of probation) that include:

 

 

(1)  The written report and documentation provided by the treatment pro­gram pursuant to the contract, and

 

(2)  A written description of James Murray Bayless' progress towards recov­ery and what he has been doing during the previous three months.

 

 

(C)  Other terms of probation are as follows:

 

(1)  The State Board of Pharmacy hereby declares that James Murray Bayless' phar­macist identification card is not in good standing and thereby denies the privilege of being a preceptor and training pharmacy interns pursuant to paragraph (D)(1) of Rule 4729-3-01 of the Ohio Administrative Code.

 

 

(2)  James Murray Bayless may not serve as a responsible pharmacist.

 

(3)  James Murray Bayless may not destroy, assist in, or witness the destruction of controlled substances.

 

 

(4)  James Murray Bayless must abide by the contract from the treatment provider and any violation must be reported to the Board immediately.

 

(5)  James Murray Bayless must not violate the drug laws of the State of Ohio, any other state, or the federal government.

 

 

(6)  James Murray Bayless must abide by the rules of the State Board of Pharmacy.

 

(7)  James Murray Bayless must comply with the terms of this Order.

 

 

James Murray Bayless is hereby advised that the Board may at any time revoke probation for cause, modify the conditions of probation, and reduce or extend the period of proba­tion.  At any time during this period of probation, the Board may revoke probation for a violation occurring during the probation period.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

 

The motion was seconded by Mr. Kost and approved by the Board (Aye-8/Nay-0).

 

R-2003-024

Ms. Eastman moved that the Board adopt the following Order in the matter of Frank A. Leon, R.Ph.:

 

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-020212-038)

 

In The Matter Of:

 

FRANK A. LEON, R.Ph.

3847 Falbo Avenue

Lorain, Ohio 44052

(R.Ph. No. 03-1-07771)

 

 

INTRODUCTION

 

THE MATTER OF FRANK A. LEON CAME FOR HEARING ON AUGUST 6, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

 

 

FRANK A. LEON WAS REPRESENTED BY JACK W. BRADLEY AND THE STATE OF OHIO WAS REP­RESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

 

SUMMARY OF EVIDENCE

 

State’s Witnesses

Mark A. Kabat, Ohio State Board of Pharmacy

 

Respondent's Witnesses

1.  Reverend Douglas Koesel

2.  Frank A. Leon, R.Ph., Respondent

 

 

State's Exhibits

1.  Notice of Opportunity for Hearing  [02-12-02]

1A-1C.  Procedurals

1D.  Addendum Notice  [07-11-02]

2.  Amherst Police Department Incident/Offense Report  [06/09/01]

3.  Narrative Supplement  [not dated]; and memo from Don Dugger, CVS/Pharmacy Loss Prevention Representative  [06/12/01]

4.  Statement of Ronald A. Gilliand, CVS/Pharmacy District Manager  [06/09/01]

5.  Notarized Statement of Pamela Mate, CVS/Pharmacy Technician  [08/02/01]

6.  Notarized Statement of Peggy Lee Robinson, CVS Store Manager  [07/27/01]

7.  Accountability Statement for Xanax 0.25 mg  [08/14/01]

8.  Accountability Statement for Alprazolam 0.25 mg  [08/14/01]

9.  Accountability Statement for Clorazepate Dipotassium 3.75 mg  [08/15/01]

10.  Accountability Statement for Darvocet N-100  [08/13/01]

11.  Indictment, State of Ohio vs. Frank Leon, Case No. 01CR058582, Lorain County Common Pleas Court  [08/07/01]

12.  Journal Entry, State of Ohio vs. Frank Leon, Case No. 01CR058582, Lorain County Common Pleas Court  [02/25/02]

13.  Journal Entry, State of Ohio vs. Frank Leon, Case No. 01CR058582, Lorain County Common Pleas Court  [02-25-02]

14.  Judgment Entry, State of Ohio vs. Frank Leon, Case No. 01CR058582, Lorain County Common Pleas Court  [02/25/02]

 

 

Respondent's Exhibits

A.  Letter from Carla S. Park, MSSA, LSW  [02/20/02]

B.  EEG Interpretation Report from Ray Romero, M.D.  [09/11/01]; and Humility of Mary Health Partners Medical Imaging Report of Frank A. Leon  [09/11/01]

C.  Curriculum Vitae of Reverend Douglas Koesel; and Recovery Program for Frank Leon  [not dated]

D.  Letter from Michael B. Willets  [07/30/02]

 

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evi­dence, and weighed the credibility of each, the State Board of Pharmacy finds the follow­ing to be fact:

 

 

(1)  Records of the State Board of Pharmacy indicate that Frank A. Leon was licensed by the State of Ohio as a pharmacist on August 20, 1962, pursuant to examination, and is cur­rently licensed to practice pharmacy in Ohio.

 

 

(2)  Frank A. Leon did, on or about June 9, 2001, with purpose to deprive, know­ingly obtain or exert control over dangerous drugs, the property of CVS/pharmacy #3325, beyond the express or implied consent of the owner, to wit: while practic­ing pharmacy, Frank A. Leon admittedly stole the following:

 

 

8

Xanax .25mg

 

 

8

clorazepate dipotassium 3.75mg

 

 

63

Darvocet N-100

 

 

1

Lotrisone 15g tube

 

 

1

Lotrisone 45g tube

 

 

 

Additionally, Frank A. Leon has admitted to stealing Beta-Val Cream a few weeks previous to June 9, 2001.  Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.

 

 

(3)  Frank A. Leon did, on or about June 9, 2001, with purpose to deprive, know­ingly obtain or exert control over property of CVS/pharmacy #3325, the value being less than $500.00, beyond the express or implied consent of the owner, to wit: while practicing pharmacy, Frank A. Leon admittedly stole coffee, dishwashing detergent, shaving cream, and deodor­ant.  Additionally, Frank A. Leon has admitted to stealing merchandise valued at approxi­mately $20.00 per week for the preced­ing thirty-two weeks.  Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.

 

 

(4)  On February 22, 2002, Frank A. Leon pled guilty to one (1) count of Theft of Drugs, a felony of the fifth degree under Section 2913.02(A) of the Ohio Revised Code, and to one (1) count of Theft, a misdemeanor of the first degree under Sec­tion 2913.02(A) of the Ohio Revised Code. Frank A. Leon was granted intervention in lieu of conviction.  State of Ohio vs. Frank Leon, Case No. 01CR058582, Lorain County Common Pleas Court.  Such conduct indicates that Frank A. Leon is guilty of a felony or gross immorality, dishonesty or unpro­fessional conduct in the practice of pharmacy, and/or addicted to or abusing drugs to ren­der Frank A. Leon unfit to practice pharmacy within the meaning of Section 4729.16 of the Ohio Revised Code.

 

 

CONCLUSIONS OF LAW

 

(1)  The State Board of Pharmacy concludes that paragraphs (2) through (4) of the Findings of Fact constitute being guilty of a felony and gross immorality as pro­vided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.

 

 

(2)  The State Board of Pharmacy concludes that paragraphs (2) through (4) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

 

(3)  The State Board of Pharmacy concludes that paragraph (4) of the Findings of Fact con­stitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy as pro­vided in Division (A)(3) of Section 4729.16 of the Ohio Revised Code.

 

 

DECISION OF THE BOARD

 

Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby suspends indefinitely the pharmacist identification card, No. 03-1-07771, held by Frank A. Leon and such suspension is effective as of the date of the mailing of this Order.

 

 

(A)  Frank A. Leon, pursuant to Rule 4729-9-01(F) of the Ohio Administrative Code, may not be employed by or work in a facility licensed by the State Board of Pharmacy to possess or distribute dangerous drugs during such period of suspension.

 

 

(B)  Frank A. Leon, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return his identification card and license (wall certificate) to the office of the State Board of Phar­macy within ten days after receipt of this Order unless the Board office is already in pos­session of both.  The identification card and wall certificate should be sent by certified mail, return receipt requested.

 

 

Further, after twenty-four months from the effective date of this Order, the Board will con­sider any petition filed by Frank A. Leon for a hearing, pursuant to Ohio Revised Code Chapter 119., for reinstate­ment.  The Board will only consider reinstatement of the license to practice pharmacy in Ohio if the following conditions have been met:

 

 

(A)  Frank A. Leon must obtain, within sixty days after the effective date of this Order, a full psychiatric evaluation by a licensed psychiatrist and must abide by the treatment plan as designed by that psychiatrist.  The psychiatrist must provide an initial status report, which includes the recommended treatment plan, to the Board within ten days after completing the assessment.

 

 

(B)  Frank A. Leon must obtain, within sixty days after the effective date of this Order, a full medical evaluation by a licensed physician and must abide by the treatment plan as designed by that physician.  The physician must provide an initial status report, which includes the recommended treatment plan, to the Board within ten days after completing the assessment.

 

 

(C)  Frank A. Leon must enter into a contract, signed within thirty days after the effective date of this Order, with an Ohio Department of Alcohol and Drug Addic­tion Services (ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of not less than five years and, upon signing, mail a copy of the contract to the Board office.  The contract must provide that:

 

 

(1)  Random, observed urine drug screens shall be conducted at least once each month.

 

 

(a)  The urine sample must be given within twelve hours of notifica­tion.  The urine drug screen must include testing for creatinine or specific gravity of the sample as the dilutional standard.

 

 

(b)  Results of all drug screens must be negative.  Any positive re­sults, including those which may have resulted from ingestion of food, but excluding false positives which resulted from medication legitimately prescribed, indicates a violation of the contract.

 

 

(2)  Attendance is required a minimum of three times per week at an Alco­holics Anonymous, Narcotics Anonymous, and/or similar support group meeting.

 

 

(3)  The program shall immediately report to the Board any violations of the con­tract and/or lack of cooperation.

 

 

(D)  Frank A. Leon must provide, at the reinstatement petition hearing, documenta­tion of the following:

 

(1)  Compliance with the licensed psychiatrist's recommended treatment plan;

 

(2)  A report by the licensed psychiatrist regarding Frank A. Leon 's fitness for readmission into the practice of pharmacy;

 

 

(3)  Compliance with the licensed physician’s recommended treatment plan;

 

(4)  A report by the licensed physician regarding Frank A. Leon 's fitness for readmission into the practice of pharmacy;

 

 

(5)  Compliance with the contract required above (e.g.-proof of giving the urine sample within twelve hours of notification and copies of all urine screen reports, meeting attendance records, treatment program reports, etc.);

 

(6)  His efforts for providing restitution to CVS/pharmacy #3325.

 

 

(7)  Compliance with the continuing pharmacy education requirements set forth in Chapter 4729-7 of the Ohio Administrative Code as applicable and in effect on the date of petitioning the Board for reinstatement;

 

(8)  Compliance with the terms of this Order.

 

 

(E)  If reinstatement is not accomplished within three years of the effective date of this Order, Frank A. Leon must also show successful completion of the NAPLEX examination or an equivalent examination approved by the Board.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

 

The motion was seconded by Mrs. Teater and approved by the Board (Aye-8/Nay-0).

 

  5:02 p.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of creating a record in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Bruce Michael Linneman, R.Ph., Atlanta, Georgia.

 

  5:23 p.m.

The record was closed.

 

  5:26 p.m.

Mr. Braylock moved that the Board go into Executive Session for the purpose of the investigation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mr. Lipsyc and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

 

  5:30 p.m.

 

The Executive Session ended and the meeting was opened to the public.

 

R-2003-025

Ms. Eastman moved that the Board adopt the following Order in the matter of Bruce Michael Linneman, R.Ph.:

 

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-020606-058)

 

In The Matter Of:

 

BRUCE MICHAEL LINNEMANN, R.Ph.

12101 Midpines Drive, Apt. 20

Cincinnati, Ohio 45241

(R.Ph. No. 03-2-11230)

 

 

INTRODUCTION

 

THE MATTER OF BRUCE MICHAEL LINNEMANN CAME FOR CONSIDERATION ON AUGUST 6, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

 

 

BRUCE MICHAEL LINNEMANN WAS NOT PRESENT NOR WAS HE REPRESENTED BY COUNSEL, AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

 

SUMMARY OF EVIDENCE

State's Witnesses

1.  Michael Cluxton, Ohio State Board of Pharmacy

 

Respondent's Witnesses

None

 

 

State's Exhibits

1.  Summary Suspension Order/Notice Of Opportunity For Hearing letter  [06/06/02]

1A-1B.  Procedurals

2.  Notarized Statement of Gloria Burrell   [02-15-02]

3.  Notarized Statement of Nancy McKillop  [02-15-02]

4.  Notarized Statement of Jaime Havrilla  [02-21-02]

5.  Case Inquiry Report by Becky Hillyer  [01-25-02]

6.  Alcohol Testing Form (Non-DOT)  [01-04-02]

7.  Walgreens Breath Alcohol Form  [01-04-02]

8.  Rx C109666  [05-08-02]

9.  Notarized Statement of Leo Wayne, M.D.  [07-12-02]

10.  Sharonville Police Department records regarding Bruce Michael Linnemann  [02-06-02 to 03-13-02]

 

Respondent's Exhibits

None

 

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witness, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the follow­ing to be fact:

 

 

(1)  On June 6, 2002, Bruce Michael Linnemann was notified by letter of his right to a hearing, his rights in such hearing, and his right to submit any contentions in writing.

 

(2)  As demonstrated by facsimile confirmation dated June 26, 2002, Bruce Michael Linnemann received the letter of June 6, 2002, informing him of the allegations against him, and his rights.

 

(3)  Bruce Michael Linnemann has not responded in any manner to the letter of June 6, 2002, and has not requested a hearing in this matter.

 

 

(4)  Records of the State Board of Pharmacy indicate that Bruce Michael Linnemann was originally licensed by the State of Ohio as a pharmacist on August 4, 1975, pursuant to examination, and that his license to practice pharmacy in Ohio was summarily suspended effective June 6, 2002.

 

 

(5)  Bruce Michael Linnemann is addicted to or abusing liquor or impaired physi­cally or mentally to such a degree as to render him unfit to practice pharmacy, to wit: on January 4, 2002, Bruce Michael Linnemann was observed while practicing pharmacy, to have slurred speech, being forgetful of things just told him, having difficulty in maintaining balance, and shaking.  Approximately six (6) hours after Bruce Michael Linnemann began his shift, he tested .204 and again .218 breath-blood alcohol content (B.A.C.).

 

 

(6)  Bruce Michael Linnemann did, on or about May 8, 2002, intentionally make and/or knowingly possess a false or forged prescription, to wit: Bruce Michael Linnemann admit­tedly created, and dispensed to himself, Rx 109666 for ten (10) unit doses of hydrocodone 10mg with APAP 650mg.  Such conduct is in violation of Section 2925.23(B) of the Ohio Revised Code.

 

 

(7)  Bruce Michael Linnemann did, from April 12, 2002, through May 29, 2002, with pur­pose to deprive, knowingly obtain or exert control over dangerous drugs, the property of CVS pharmacies, beyond the express or implied consent of the owner, to wit: Bruce Michael Linnemann has admittedly stolen an excess of fifty (50) tab­lets of hydrocodone products from various CVS pharmacies while practicing phar­macy as a "floater" among stores.  Such conduct is in violation of Section 2913.02 of the Ohio Revised Code.

 

 

CONCLUSIONS OF LAW

 

(1)  The State Board of Pharmacy concludes that paragraphs (5) through (7) of the Findings of Fact constitute being guilty of gross immorality as provided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.

 

 

(2)  The State Board of Pharmacy concludes that paragraphs (5) through (7) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

 

(3)  The State Board of Pharmacy concludes that paragraph (5) of the Findings of Fact con­stitutes being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy as provided in Division (A)(3) of Section 4729.16 of the Ohio Revised Code.

 

 

(4)  The State Board of Pharmacy concludes that paragraph (6) of the Findings of Fact con­stitutes being guilty of willfully violating, conspiring to violate, attempting to violate, or aiding and abetting the violation of provisions of Chapter 2925. of the Revised Code as pro­vided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

 

DECISION OF THE BOARD

 

Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby removes the Summary Suspension Order issued to Bruce Michael Linnemann on June 6, 2002.

 

 

Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy takes the following actions in the matter of Bruce Michael Linnemann:

 

 

(A)  On the basis of the Findings of Fact and paragraph (1) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharmacist identification card, No. 03-2-11230, held by Bruce Michael Linnemann effective as of the date of the mailing of this Order.

 

 

(B)  On the basis of the Findings of Fact and paragraph (2) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharmacist identification card, No. 03-2-11230, held by Bruce Michael Linnemann effective as of the date of the mailing of this Order.

 

 

(C)  On the basis of the Findings of Fact and paragraph (3) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharmacist identification card, No. 03-2-11230, held by Bruce Michael Linnemann effective as of the date of the mailing of this Order.

 

 

(D)  On the basis of the Findings of Fact and paragraph (4) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby revokes the pharmacist identification card, No. 03-2-11230, held by Bruce Michael Linnemann effective as of the date of the mailing of this Order.

 

 

Pursuant to Section 4729.16(B) of the Ohio Revised Code, Bruce Michael Linnemann must return his identification card and license (wall certificate) to the office of the State Board of Pharmacy within ten days after receipt of this Order unless the Board office is already in possession of both.  The identification card and wall certificate should be sent by certified mail, return receipt requested.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

 

The motion was seconded by Mrs. Teater and approved by the Board (Aye-8/Nay-0).

 

  5:35 p.m.

The meeting was recessed until Wednesday, August 7, 2002.

 

 

WEDNESDAY, AUGUST 7, 2002

 

  8:27 a.m.

ROLL CALL

 

The State Board of Pharmacy reconvened in Room East-B, 31st Floor, Vern Riffe Center for Government and the Arts, 77 South High Street, Columbus, Ohio with the following members present:

 

 

Diane C. Adelman, R.Ph. (President); Robert P. Giacalone, R.Ph. (Vice-President); Suzanne R. Eastman, R.Ph.; Elizabeth I. Gregg, R.Ph.; Lawrence J. Kost, R.Ph.; Nathan S. Lipsyc, R.Ph.; Dorothy S. Teater, Public Mem­ber; and James E. Turner, R.Ph.

 

 

Mr. McMillen discussed his licensing report with the Board.

 

R-2003-026

Mr. Keeley discussed a request from Ohioans First that the Board support their efforts in reducing medical errors by joining in a statement to be issued by multiple agencies.  The consensus of the Board was that it would be acceptable to comply with this request.

 

  8:32 a.m.

Mr. Braylock arrived and joined the meeting in progress.

 

  8:35 a.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of creating a record in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Phoenix Pharmaceutical Lab & Consulting, Pineville, North Carolina.

 

  8:46 a.m.

The record was closed.

 

  8:49 a.m.

The Board took a brief recess.

 

  9:03 a.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of John R. Tomko, R.Ph., Hubbard.  Mr. Kost recused himself from the hearing.

 

10:26 a.m.

The hearing ended and the record was closed.  The Board took a brief recess.

 

10:45 a.m.

The Board was joined by Assistant Attorney General Sally Ann Steuk for the purpose of conducting an adjudication hearing in accordance with Ohio Revised Code Chapters 119. and 4729. in the matter of Betty Jean Minch, R.Ph., Massillon.  Mr. Kost recused himself from the hearing.

 

12:00 p.m.

The hearing was recessed for lunch.

 

  1:13 p.m.

The hearing in the matter of Betty Jean Minch, R.Ph. resumed.

 

  1:45 p.m.

The hearing ended and the record was closed.

 

  1:48 p.m.

Mr. Turner moved that the Board go into Executive Session for the purpose of the investi­gation of complaints regarding licensees and registrants pursuant to Section 121.22(G)(1) of the Revised Code.  The motion was seconded by Mr. Giacalone and a roll call vote was conducted by President Adelman as follows: Braylock-Yes, Eastman-Yes, Giacalone-Yes, Gregg-Yes, Kost-Yes, Lipsyc-Yes, Teater-Yes, and Turner-Yes.

 

  2:45 p.m.

R-2003-027

The Executive Session ended and the meeting was opened to the public.  Mr. Braylock moved that, pursuant to Section 3719.121 of the Revised Code, the Board summarily suspend the license to practice pharmacy belonging to Alan P. Horvath, R.Ph. (03-3-21869) due to the fact that a continuation of his professional practice presents a danger of immediate and serious harm to others.  The motion was seconded by Mr. Lipsyc and approved by the Board (Aye-7/Nay-1).

 

R-2003-028

Mr. Giacalone moved that the Board adopt the following Order in the matter of Betty Jean Minch, R.Ph.:

 

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-020614-062)

 

In The Matter Of:

 

BETTY JEAN MINCH, R.Ph.

110 Edwin Avenue, S.E.

Massillon, Ohio  44646

(R.Ph. No. 03-1-12312)

 

 

INTRODUCTION

 

THE MATTER OF BETTY JEAN MINCH CAME FOR HEARING ON AUGUST 7, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

 

 

BETTY JEAN MINCH WAS REPRESENTED BY EUGENE F. McSHANE AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

 

SUMMARY OF EVIDENCE

State’s Witnesses

1.  David Gallagher, Ohio State Board of Pharmacy

 

Respondent's Witnesses

1.  Betty Jean Minch, R.Ph., Respondent

 

 

State's Exhibits

1.  Notice of Opportunity for Hearing letter  [06-14-02]

1A-1E.  Procedurals

2.  Rx 03114 289578  [09-17-01]

3.  Rx 03114 289599  [09-18-01]

4.  Rx 03114 289720  [09-18-01]

5.  Rx 03114 289992  [09-21-01]

6.  Rx 03114 289994  [09-21-01]

7.  Rx 03114 290036  [09-21-01]

8.  Rx 03114 290069  [09-21-01]

9.  Rx 03114 290126  [09-21-01]

 

10.  Rx 03114 290129  [09-21-01]

11.  Rx 03114 290135  [09-22-01]

12.  Rx 03114 291245  [10-01-01]

13.  Rx 03114 298369  [11-26-01]

 

14.  Rx 03114 306036  [01-25-02]

15.  Rx 03114 306202  [01-25-02]

16.  Rx 03114 306281  [01-26-02]

17.  Rx 03114 307291  [02-04-02]

18.  Written Statement by Respondent  [02-26-02]

19.  Customer History Report of Betty Minch  [02-25-02]

 

 

Respondent's Exhibits

A.  Continuing Pharmaceutical Education Certificates  [02-26-02 to 03-07-02]

B.  Complaint For Divorce, Betty Minch vs. Mark Minch, Case No. 2002DR00965, Stark County Common Pleas Court  [07-03-02]

C.  Letter from Larry P. Iorio  [07-23-02]

D.  Letter from Steven E. Connelly, M.D.  [07-23-02]

E.  Letter from Stephanie Bradford, ACSW, LISW  [08-01-02]

 

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the follow­ing to be fact:

 

 

(1)  Records of the State Board of Pharmacy indicate that Betty Jean Minch was origi­nally licensed by the State of Ohio as a pharmacist on March 6, 1978, pursuant to examination.  On September 18, 2001, the Ohio State Board of Pharmacy received an Application for License Renewal as a Pharmacist from Betty Jean Minch; however, Ms. Minch's license to practice pharmacy in Ohio had expired as of September 15, 2001.

 

 

(2)  Betty Jean Minch did, on or about the following dates, while not being a regis­tered phar­macist or pharmacy intern, dispense medication, to wit: after allowing her license to prac­tice pharmacy to lapse, and prior to its renewal, Betty Jean Minch dispensed the following prescriptions:

 

 

 

Rx #

Dispensed

 

 

 

03114 289578

09/17/01

 

 

 

03114 289599

09/18/01

 

 

 

03114 289720

09/18/01

 

 

 

03114 289992

09/21/01

 

 

 

03114 289994

09/21/01

 

 

 

03114 290036

09/21/01

 

 

 

03114 290069

09/21/01

 

 

 

03114 290126

09/21/01

 

 

 

03114 290129

09/21/01

 

 

 

03114 290135

09/22/01

 

 

 

03114 291245

10/01/01

 

 

 

03114 298369

11/26/01

 

 

 

03114 306036

01/25/02

 

 

 

03114 306202

01/25/02

 

 

 

03114 306281

01/26/02

 

 

 

03114 307291

02/04/02

 

 

 

Such conduct is in violation of Section 4729.28 of the Ohio Revised Code.

 

(3)  Betty Jean Minch is impaired physically or mentally to such a degree as to render her unfit to practice pharmacy, to wit: Betty Jean Minch admitted to a Board agent that, due to a severe depression, she was unable to complete her continuing pharmacy education requirements and her 2002 license renewal; and that she was having personal problems and had a hard time functioning.

 

 

CONCLUSIONS OF LAW

 

(1)  The State Board of Pharmacy concludes that paragraphs (2) and (3) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

 

(2)  The State Board of Pharmacy concludes that paragraph (2) of the Findings of Fact con­stitutes being guilty of willfully violating, conspiring to violate, attempting to violate, or aiding and abetting the violation of provisions of Chapter 4729. of the Revised Code as provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

 

DECISION OF THE BOARD

 

Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy takes the following actions in the matter of Betty Jean Minch:

 

 

(A)  On the basis of the Findings of Fact and paragraph (1) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby approves the issuance of a renewal phar­macist identification card, No. 03-1-12312, to Betty Jean Minch to practice pharmacy in Ohio and places Betty Jean Minch on probation for two years from the date the identifica­tion card is issued, with the following conditions:

 

 

(1)  Betty Jean Minch must obtain, within sixty days after the effective date of this Order, a full psychiatric evaluation by a licensed psychiatrist.  The psychiatrist must provide an initial status report, which includes the recom­mended treatment plan, to the Board and to her physician within ten days after complet­ing the assessment.

 

 

(2)  Betty Jean Minch must continue to follow the treatment plan, with coun­sel­ing, set forth by Steven E. Connelly, M.D. or another program acceptable to the Board.

 

 

(B)  On the basis of the Findings of Fact and paragraph (2) of the Conclusions of Law set forth above, the State Board of Pharmacy hereby imposes a monetary penalty of one hun­dred dollars ($100.00) on Betty Jean Minch and payment of the monetary penalty is due and owing within thirty days of the mailing of this Order.  The remittance should be made payable to the "Treasurer, State of Ohio" and mailed with the enclosed form to the State Board of Pharmacy, 77 South High Street, Room 1702, Columbus, Ohio 43215-6126.

 

 

(C)  Other terms of probation are as follows:

 

(1)  The State Board of Pharmacy hereby declares that Betty Jean Minch's pharmacist identification card is not in good standing and thereby denies the privilege of being a preceptor and training pharmacy interns pursuant to paragraph (D)(1) of Rule 4729-3-01 of the Ohio Administrative Code.

 

(2)  Betty Jean Minch may not serve as a responsible pharmacist.

 

 

(3)  Betty Jean Minch may not work in a pharmacy more than forty hours per week during the first year of probation.

 

(4)  Betty Jean Minch must not violate the drug laws of the state of Ohio, any other state, or the federal government.

 

 

(5)  Betty Jean Minch must abide by the rules of the State Board of Phar­macy.

 

(6)  Betty Jean Minch must comply with the terms of this Order.

 

 

Betty Jean Minch is hereby advised that the Board may at any time revoke probation for cause, modify the conditions of probation, and reduce or extend the period of probation.  At any time during this period of probation, the Board may revoke probation for a violation occurring during the probation period.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY (Aye-5/Nay-2).

MOTION CARRIED.

SO ORDERED.

 

 

The motion was seconded by Mr. Lipsyc and approved by the Board (Aye-5/Nay-2/­Abstain-1[Kost]).

 

R-2003-029

Ms. Eastman moved that the Board adopt the following Order in the matter of John R. Tomko, R.Ph.:

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-020307-045)

 

In The Matter Of:

 

JOHN R. TOMKO, R.Ph.

5812 Watson Street S.E.

Hubbard, Ohio 44425

(R.Ph. No. 03-2-15734)

 

 

INTRODUCTION

 

THE MATTER OF JOHN R. TOMKO CAME FOR HEARING ON AUGUST 7, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

 

 

JOHN R. TOMKO WAS REPRESENTED BY JOHN R. SHULTZ AND THE STATE OF OHIO WAS REP­RESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

 

SUMMARY OF EVIDENCE

State’s Witnesses

1.  Joann D. Predina, R.Ph., Ohio State Board of Pharmacy

 

Respondent's Witnesses

1.  John R. Tomko, R.Ph., Respondent

2.  Joseph Gioiello, R.Ph.

3.  Patricia A. Tomko, R.Ph.

 

 

State's Exhibits

1.  Summary Suspension Order/Notice of Opportunity For Hearing  [03-07-02]

1A-1C.  Procedurals

1D.  Amendment Notice  [04-23-02]

1E.  Procedurals

1F. 

 

2.

3. 

4. 

5. 

6. 

8. 

 

9.

10.

 

 

Respondent's Exhibits

A.  Pharmacist’s Recovery Contract for John Tomko  [04-28-02]

B. 

C.  Support Group Attendance Records  [03-04-02 to 07-30-02]

D. 

E.  Drug Screen Reports  [05-16-02 to 07-25-02]

F.  Drug Screen Reports  [03-04-02 to 07-29-02]

G.  Letters of Support from Patricia A. Tomko, R.Ph.  [07-31-02]; Roy Perry, R.Ph. [not dated]; Murphy Lewis, M.Ed., CCDC-III-E  [08-06-02]; Reverend Timothy H. O’Neill, Pastor  [07-12-02]; Ralph Rich  [07-14-02]; Gabriel J. Illes Jr., R.Ph.  [06-19-02]; Richard Rumelfanger, R.Ph.  [not dated]; Peter Cefrick Jr., R.Ph.  [06-20-02]; David M. Tamulonis, R.Ph.  [06-28-02]; Joseph C. Salmen, R.Ph.  [07-29-02]; Todd R. Jaros, R.Ph.  [07-11-02]; Christopher M. Holzman, R.Ph.  [07-12-02]; and Eugene O’Brien, Ph.D.  [07-23-02]

H.  Continuing Pharmaceutical Education Certificates  [08-26-99 to 04-28-02]

 

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witnesses, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the follow­ing to be fact:

 

 

(1)  Records of the State Board of Pharmacy indicate that John R. Tomko was licensed by the State of Ohio as a pharmacist on August 8, 1984, pursuant to examination, and that his license to practice pharmacy in Ohio was summarily suspended effective March 7, 2002.

 

 

(2)    John R. Tomko is addicted to the use of controlled substances.

 

 

(3)

 

 

(4)

 

 

(5)

 

 

CONCLUSIONS OF LAW

 

(1)  The State Board of Pharmacy concludes that paragraphs (3) through (5) of the Findings of Fact constitute being guilty of         gross immorality as pro­vided in Division (A)(1) of Section 4729.16 of the Ohio Revised Code.

 

(2)  The State Board of Pharmacy concludes that paragraphs (2) through (5) of the Findings of Fact constitute being guilty of dishonesty and unprofessional conduct in the practice of pharmacy as provided in Division (A)(2) of Section 4729.16 of the Ohio Revised Code.

 

 

(3)  The State Board of Pharmacy concludes that paragraphs (2) through (5) of the Findings of Fact constitute being addicted to or abusing liquor or drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy as provided in Divi­sion (A)(3) of Section 4729.16 of the Ohio Revised Code.

 

(4)  The State Board of Pharmacy concludes that paragraph (5) of the Findings of Fact constitutes being guilty of willfully violating, conspiring to violate, attempting to violate, or aiding and abetting the violation of provisions of Chapter 2925. of the Revised Code as provided in Division (A)(5) of Section 4729.16 of the Ohio Revised Code.

 

 

DECISION OF THE BOARD

 

Pursuant to Section 3719.121 of the Ohio Revised Code, the State Board of Pharmacy hereby removes the Summary Suspension Order issued to John R. Tomko on March 7, 2002.

 

 

Pursuant to Section 4729.16 of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby suspends indefinitely the pharmacist identification card, No. 03-2-15734, held by John R. Tomko and such suspension is effective as of the date of the mail­ing of this Order.

 

 

(A)  John R. Tomko, pursuant to Rule 4729-9-01(F) of the Ohio Administrative Code, may not be employed by or work in a facility licensed by the State Board of Phar­macy to possess or distribute dangerous drugs during such period of suspension.

 

(B)  John R. Tomko, pursuant to Section 4729.16(B) of the Ohio Revised Code, must return his identification card and license (wall certificate) to the office of the State Board of Phar­macy within ten days after receipt of this Order unless the Board office is already in posses­sion of both.  The identification card and wall certificate should be sent by certified mail, return receipt requested.

 

 

Further, after nine months from the effective date of this Order, the Board will consider any petition filed by John R. Tomko for a hearing, pursuant to Ohio Revised Code Chapter 119., for reinstate­ment.  The Board will only consider reinstatement of the license to practice pharmacy in Ohio if the following conditions have been met:

 

 

(A)  John R. Tomko must enter into a contract, signed within thirty days after the effective date of this Order, with an Ohio Department of Alcohol and Drug Addic­tion Services (ODADAS) treatment provider or a treatment provider acceptable to the Board for a period of not less than five years and, upon signing, mail a copy of the contract to the Board office.  The contract must provide that:

 

 

(1)  Random, observed urine drug screens shall be conducted at least once each month.

 

 

(a)  The urine sample must be given within twelve hours of notifica­tion.  The urine drug screen must include testing for creatinine or specific gravity of the sample as the dilutional standard.

 

(b)  Results of all drug screens must be negative.  Any positive results, including those which may have resulted from ingestion of food, but excluding false positives which resulted from medication legitimately prescribed, indicates a violation of the contract.

 

 

(2)  Attendance is required a minimum of three times per week at an Alco­holics Anonymous, Narcotics Anonymous, and/or similar support group meeting.

 

(3)  The program shall immediately report to the Board any violations of the con­tract and/or lack of cooperation.

 

 

(B)  John R. Tomko must demonstrate satisfactory proof to the Board that he is no longer addicted to or abusing drugs or impaired physically or mentally to such a degree as to render him unfit to practice pharmacy.

 

(C)  John R. Tomko must provide, at the reinstatement petition hearing, documenta­tion of the following:

 

 

(1)  Compliance with the contract required above (e.g.-proof of giving the sample within twelve hours of notification and copies of all drug screen reports, meeting attendance records, treatment program reports, etc.);

 

(2)  Compliance with the continuing pharmacy education requirements set forth in Chapter 4729-7 of the Ohio Administrative Code as applicable and in effect on the date of petitioning the Board for reinstatement;

 

(3)  Compliance with the terms of this Order.

 

 

(D)  If reinstatement is not accomplished within three years of the effective date of this Order, John R. Tomko must also show successful completion of the NAPLEX examination or an equivalent examination approved by the Board.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

 

The motion was seconded by Mrs. Teater and approved by the Board (Aye-6/Nay-1/­Abstain-1[Kost]).

 

R-2003-030

Mr. Turner then moved that the Board adopt the following Order in the matter of Phoenix Pharmaceutical Lab & Consulting:

 

ORDER OF THE STATE BOARD OF PHARMACY

(Docket No. D-020514-056)

 

In The Matter Of:

 

PHOENIX PHARMACEUTICAL LAB & CONSULTING

Mohammad Banawan, R.Ph.

10829 Pineville Road, Suite 6

Pineville, North Carolina 28134

 

 

INTRODUCTION

 

THE MATTER OF PHOENIX PHARMACEUTICAL LAB & CONSULTING CAME FOR CONSIDERA­TION ON AUGUST 7, 2002, BEFORE THE FOLLOWING MEMBERS OF THE BOARD: DIANE C. ADELMAN, R.Ph. (presiding); GREGORY BRAYLOCK, R.Ph.; SUZANNE R. EASTMAN, R.Ph.; ROBERT P. GIACALONE, R.Ph.; ELIZABETH I. GREGG, R.Ph.; LAWRENCE J. KOST, R.Ph.; NATHAN S. LIPSYC, R.Ph.; DOROTHY S. TEATER, PUBLIC MEMBER; AND JAMES E. TURNER, R.Ph.

 

PHOENIX PHARMACEUTICAL LAB & CONSULTING WAS NOT PRESENT NOR WAS IT REPRE­SENTED BY COUNSEL, AND THE STATE OF OHIO WAS REPRESENTED BY SALLY ANN STEUK, ASSISTANT ATTORNEY GENERAL.

 

 

SUMMARY OF EVIDENCE

State’s Witnesses

Robert Cole, Ohio State Board of Pharmacy

 

Respondent's Witnesses

None

 

 

State's Exhibits

1.  Proposal to Deny/Notice of Opportunity for Hearing  [05-14-02]

2.  Application for Registration as a Terminal Distributor of Dangerous Drug  [03-08-02]

3.  Copy of Articles of Incorporation of Phoenix Pharmaceutical Lab and Consulting Inc., North Carolina Dept. of The Secretary of State  [10-19-00]

4.  Inspection Report (New) of Phoenix Pharmaceutical Lab, North Carolina Board of Pharmacy  [12-12-01]

5.  Certification of Licensure by the North Carolina Board of Pharmacy for Mohammad Fawzy Banawan  [07-02-01] and Phoenix Pharmaceutical Lab  [02-26-01]

6.  Prescription Consultation.com  - Online Pharmacy Future FAQ  [03-11-02]

 

Respondent's Exhibits

None

 

 

FINDINGS OF FACT

 

After having heard the testimony, observed the demeanor of the witness, considered the evidence, and weighed the credibility of each, the State Board of Pharmacy finds the follow­ing to be fact:

 

 

(1)  On May 14, 2002, Mohammad Banawan was notified by letter of his right to a hear­ing, his rights in such hearing, and his right to submit any contentions in writing.

 

 

(2)  As demonstrated by return receipt dated May 16, 2002, Mohammad Banawan received the letter of May 14, 2002, informing him of the Board's proposal to deny his Application For Registration As A Terminal Distributor Of Dangerous Drugs, and his rights.

 

(3)  Mohammad Banawan has not responded in any manner to the letter of May 14, 2002, and has not requested a hearing in this matter.

 

 

(4)  Records of the State Board of Pharmacy indicate that Mohammad Banawan is the Vice President and Pharmacy Manager for Phoenix Pharmaceutical Lab & Con­sulting.  Records further indicate that Mohammad Banawan submitted an applica­tion as a Terminal Distri­butor of Dangerous Drugs on or about March 8, 2002.

 

 

(5)  Phoenix Pharmaceutical Lab & Consulting is not equipped as to land, buildings, and equipment to properly carry on the business of a terminal distributor of dan­gerous drugs within the category applied for licensure by the Board, to wit: the pharmacy has indicated that it will accept prescriptions from patients who have not met face-to-face with a physi­cian.  A physician will only view a photographic identi­fication prior to authorizing the dis­pensing of medications.  When dispensing medi­cation in this manner, Phoenix Pharmaceuti­cal Lab & Consulting does not have the necessary facilities to properly conduct the business of a terminal distributor of dangerous drugs.

 

 

CONCLUSION OF LAW

 

The State Board of Pharmacy concludes that paragraph (5) of the Findings of Fact consti­tutes failure to meet the qualifications set forth in Division (A) of Section 4729.55 of the Ohio Revised Code.

 

 

DECISION OF THE BOARD

 

Pursuant to Section 4729.55(A) of the Ohio Revised Code, and after consideration of the record as a whole, the State Board of Pharmacy hereby refuses to issue a license for Phoenix Pharmaceutical Lab & Consulting and, therefore, denies the Application for Registration as a Terminal Distributor of Dangerous Drugs submitted by Mohammad Banawan and received by the Board on March 8, 2002.

 

THIS ORDER WAS APPROVED BY A VOTE OF THE STATE BOARD OF PHARMACY.

MOTION CARRIED.

SO ORDERED.

 

 

The motion was seconded by Mrs. Gregg and approved by the Board (Aye-8/Nay-0).

 

  2:53 p.m.

Ms. Eastman moved that the Board receive Per Diem as follows:

 

 

 

PER DIEM

08/05

08/06

08/07

Total

 

 

 

Adelman

1

1

1

3

 

 

 

Braylock

1

1

1

3

 

 

 

Eastman

1

1

1

3

 

 

 

Giacalone

1

1

1

3

 

 

 

Gregg

1

1

1

3

 

 

 

Kost

1

1

1

3

 

 

 

Lipsyc

1

1

1

3

 

 

 

Teater

1

1

1

3

 

 

 

Turner

1

1

1

3

 

 

 

 

The motion was seconded by Mrs. Gregg and approved by the Board (Aye-8/Nay-0).

 

  2:54 p.m.

Ms. Eastman moved that the meeting be adjourned.  The motion was seconded by Mrs. Teater and approved (Aye-8/Nay-0).

 

 

THE BOARD APPROVED THESE MINUTES

SEPTEMBER 10, 2002